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1. INTRODUCTION 
1.1 Influenza viruses  
Influenza viruses (IV) are among the most important respiratory pathogens in human 
population [1] and constitute a significant threat to global health with 3 to 5 million of severe 
IV infections and about 250 000 to 500 000 lethal cases per year [2, 3]. Considering the high 
IV prevalence and its capacity to cross the interspecies barrier together with easy adaptation 
to a new host [4], they are one of the greatest public health concerns worldwide. 
1.1.1 Structure and nomenclature 
IV are negative sense single-stranded segmented RNA viruses with a lipid-containing 
envelope (Figure 1-1). Three genetically and antigenically distinct IV subtypes, A, B and C 
belong, together with thogoto- and isaviruses, to the Orthomyxoviridae family. In this thesis 
the focus is on influenza A viruses (IAV) which are responsible for annual epidemics as well 
as pandemic outbreaks [5]. IAV can be subtyped based on antigenic properties of their 
surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) [6] (Figure 1-1). 
Currently, strains from 18HA subtypes and 11NA subtypes have been identified [7, 8].  
HA 
M2 
NA 
vRNP 
M1 
Membrane 
NEP 
RNA 
Polymerase 
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Figure 1-1. Schematic picture representing Influenza virus structure. HA, hemagglutinin; vRNP, viral 
ribonucleoprotein; M2, transmembrane protein M2; M1, matrix protein; NEP, nuclear export protein; NA, 
neuraminidase. Addapted from http://visual-science.com.  
All known subtypes of IAV can infect birds, except subtypes H17N10 and H18N11 (found in 
bats). Only two IAV subtypes (H1N1 and H3N2) are, together with influenza B viruses, 
seasonally circulating among humans, whereas highly pathogenic avian IV (e.g. H5N1 or 
H7N9) infect humans occasionally with high lethality, and bear a putative pandemic threat. 
The IAV genome contains 8 segmented RNA encoding at least 11-12 proteins. Three gene 
segments encode the polymerase polypeptides PB1, PB2 and PA and two smaller proteins, 
mitochondria-associated protein (PB1-F2) and N40 [9].  
Surface glycoprotein HA is playing an important role in host tropism as it binds to host cell 
receptors containing N-acetyl sialic acid (SA) moieties. Human IAV mainly recognize 
receptors with terminal α-2,6-SA moieties, found on bronchial epithelial cells of the upper 
respiratory tract (URT), whereas avian strains predominantly prefer α-2,3-SA abundantly 
expressed on epithelial cells in the intestinal tract of birds and lower respiratory tract (LRT) 
of humans. NA is crucial for proper budding and release of progeny virions. Viral RNA is 
encapsidated by a viral nucleoprotein (NP) and bound to a heterotrimer PB1, PB2 and PA 
forming the viral polymerase, that together compose viral ribonucleoprotein (vRNP) 
complex. The matrix 1 (M1) protein forms a shell underlying the lipid bilayer membrane of 
the virion. M1 interacts with cytoplasmic domains of the surface glycoproteins and vRNP 
complexes. The lipid bilayer envelope contains transmembrane M2 protein as well as HA and 
NA. M1 is a structural protein important for the nuclear export of viral RNA and viral 
budding, whereas M2 functions as an ion channel. The IV genome encodes for two additional 
proteins important for viral replication: the nonstructural 1 (NS1) protein is an interferon 
signaling antagonist and regulates cell apoptosis, and NEP (nuclear export protein) that 
facilitates nuclear export of the vRNP complexes.  
1.1.2 Epidemiology 
IV cause widespread illness yearly, named seasonal influenza, during fall and winter in the 
northern hemisphere. Most influenza epidemics are caused by a predominant serotype, but 
different viruses may appear sequentially or simultaneously. IVs are evolutionary dynamic 
viruses with high mutation rates [10] directed by adaptation to host cell factors and change in 
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antigenicity to escape from the immune response of the host. HA and NA viral proteins show 
the highest genetic variability, which allows IV to evade pre-existing immunity. Genetic 
reassortment with other IV strains, so called antigenic shift, is responsible for IV pandemics 
[11]. In contrast, antigenic drift describes accumulation of mutations throughout the genome 
and results in seasonally recurrent infection waves, as these mutations render IV non-
susceptible to detection by pre-existing anti-HA or anti-NA antibodies. Most IAV pandemics 
cause higher morbidity and mortality rates than seasonal epidemics during the inter-pandemic 
periods. Recording history, different antigenic subtypes of influenza A – H1N1, H2N2 and 
H3N2 – created a pandemic wave in the 20th century in 1918, 1957 and 1968 respectively, 
causing high mortality rates [12]. In March 2009, an outbreak of a novel reassorted H1N1 
virus started in Mexico [13-16] and rapidly expanded across the globe. As human and avian 
IV bind to different SA receptors as well as avian IV show limited replication in humans, 
avian influenza viruses were initially thought to be incapable of causing human infection. 
However, in the past decade, extensive numbers of sporadic cases and local outbreaks of 
avian IAV infections as H5N1[17, 18], H7N7 [19, 20], H7N3 [21] and H7N2, H7N9, H9N2 
[22, 23] in humans have occurred, some of them with high lethality, raising pandemic 
concern.  
1.1.3 Influenza cycle within the infected cell and virus tropism 
In the initial phase of IAV replication, the viral HA binds to host cell receptors containing α-
2,6-linked or α-2,3-linked SA moieties [6] (Figure 1-2). The virion enters the cell by 
cathepsin-1 mediated endocytosis and an HA-dependent fusion of endosomal and viral 
membrane takes place. Acidification of endocytic vesicle opens M2 ion channel, resulting in 
dissociation of the RNP complexes that contain the viral genome. The viral RNA is imported 
to the nucleus via importin-α1 and dependently of NP protein, where the transcription and 
replication of the viral genome occurs. The host cellular machinery produces new viral 
proteins, as well as negative and positive-oriented viral RNA copies. Negative-oriented viral 
RNA copies accumulate at lipid raft domains, meanwhile positive-oriented serve either as 
template or as mRNA. After RNP assembly and budding, the new virions are released outside 
of the cell. Release from the host cell is mediated by NA, which cleaves SA-containing 
receptors for virion release from the membrane.     
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Figure 1-2. IAV replication cycle in infected host cells [24]. The virion is endocytosed after interaction between 
HA and sialic acids. After viral and endosomal membrane fusion, released vRNA is transported into the nucleus 
where the transcription to mRNA and new vRNA occurs. Viral protein translation takes place in cytoplasm and 
endoplasmic reticulum. New virions assemble and bud from the apical host cell membrane and are released via 
action of NA. 
1.1.4 Host immune response to Influenza A virus  
The host´s immune system is strongly activated during IAV infection. Epithelial cells of 
respiratory tract are able to mount an antiviral response upon viral detection by pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLR), the retinoic acid-inducible 
gene I (RIG-I) protein [25], protein kinase R (PKR) and nucleotide oligomerization domain 
(NOD)-like receptor family (Figure 1-3). The TLR involved in recognizing IAV infection are 
expressed in the endosomes to sense double stranded RNA (dsRNA) occurring in virus-
infected cells (TLR3), or single stranded viral RNA (ssRNA) that occurs during viral 
replication in endosomal compartments (TLR7/8) [26-29]. Cytoplasmic RIG-I receptors 
recognize 5’-triphosphates bearing viral RNA [30]. The NOD-like receptor family member 
pyrin domain-containing 3 (NLRP3), an inflammasome receptor, recognizes viral RNA 
within the cytosol of infected cells. The signalling cascade of TLRs, except for TLR3, starts 
with activation of myeloid differentiation primary response gene 88 (MyD88). Subsequently, 
MyD88 activates tumor necrosis factor (TNF) receptor associated factor 6 (TRAF6), either 
directly or via Interleukin-1 receptor (IL-1R)-associated kinase (IRAK 1). This leads to 
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activation of mitogen-activated kinases (MAPKs) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB). TLR3 cascade is initially activated via TRIF (TIR 
domain containing adapter inducing interferon β) eventually mobilising NF-κB and IRF3 
(interferon regulatory factor 3) [31, 32]. RIG-I is crucial for viral detection and type I IFN 
production in infected epithelial cells, dendritic cells (DCs) and alveolar macrophages (AM) 
[33]. Its activation results in conformational changes exposing caspase activation and 
recruitment domains (CARDS) to ubiquitination by tripartite motif 25 (TRIM25) – an IFN-
inducible E3 ubiquitin ligase. In the following, RIG-I associates with mitochondrial antiviral 
signaling protein (MAVS) and induces IRF3 and NF-κB activation [32, 33]. TLR3/7/8 and 
RIG-I trigger high levels of type I IFN production, to induce an anti-viral state, however, this 
occurs at the cost of a frequently exaggerated immune response and recruitment of high 
numbers of damage-inducing inflammatory cells [29, 34, 35].  
The interferons (IFNs) are a group of secreted antiviral cytokines. This family of cytokines is 
now recognized as the first line of defense against viral infection. Three classes of IFN have 
been identified (I to III) and they are classified according to the receptor complex they are 
signaling through. IFNα/β will be further referred as type I IFNs and is in the focus of this 
study. The binding of type I IFNs to the heterodimeric IFNα receptor (IFNAR) initiates a 
signaling cascade, inducing more than 300 IFN-stimulated genes (ISGs) such as – MX, 2’5’-
oligoadenylate synthetase (OAS), viperin, and many others, that serve as effectors to limit 
viral replication [29, 32, 34, 35] in infected and neighbouring cells by initiating an 
intracellular anti-viral programme. Type I IFN secretion is induced by IAV in alveolar 
macrophages (AM), DCs and infected lung alveolar epithelial cells (AECs) [29, 36, 37]. 
Generally, type I IFN have been attributed beneficial role in IAV induced acute lung injury 
(ALI) by decreasing viral load [38], when protecting cells from viral attack in the early 
course of the infection. Recently, however, many reports demonstrated detrimental IFN 
effects, especially when high IFN levels persist after viral clearance, e.g. by triggering TNF-
related apoptosis-induced ligand (TRAIL) production causing apoptotic lung injury during 
IAV infection [39]. In addition, IAV infection of epithelial cells induces expression of many 
pro-inflammatory cytokines and chemokines such as – IL-1β, IL-6, IL-8, TNFα, CC 
chemokine ligand (CCL) 2, CCL3 and CCL10 and results in phagocyte activation and 
macrophage and neutrophil recruitment to sites of inflammation [29, 31, 32].  
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Figure 1-3 Host immune responses to IAV infection [25]. Toll like receptor (TLR) 3/7 is activated via 
intracellular viral RNA. This signalling pathway via IRF3, IRF7 and NFκB induces transcription of type I 
interferon and pro-inflammatory molecules. 5‘PPP dsRNA activates RIG-I. IRF3 and NFκB are activated via 
MAVS and NOD-2, and also the NLPR3 inflammasome responds to IAV infection.  These processes result in 
release of type I IFN, but also in release of many other pro-inflammatory cytokines and chemokines. 
Recruited myeloid immune cells (bone-marrow-derived macrophages and DC as well as 
neutrophils) release various pro-inflammatory mediators (IL-6, TNFα, NOS2 (nitric oxide 
synthase 2)) at the site of infection contributing to severe pathology induced by IAV [40-42]. 
DCs play an important role bridging the innate and adaptive immune system. Once the lung is 
infected with IAV, DCs acquire viral antigens both by direct infection with IAV or via 
phagocytosis of virus particles or apoptotic epithelial cells that they present to naive T and B 
lymphocytes for generation of adaptive immune responses and memory cells [43].  
However, IAV has developed various strategies to escape the innate immune response. In 
particular, the NS1 protein specifically antagonises the antiviral innate immune response. 
NS1 displays multiple functions, including inhibition of RIG-I pathway and interferon 
induced proteins such as PKR and OAS by competing with them for RNA binding [43, 44]. 
Also, the polymerase complexes have been attributed a role in evasion from IFN responses 
[32, 43-45]. In addition, IAV induces expression of SOCS (suppressor of cytokine signaling) 
proteins which inhibit IFNα/β receptor signalling on the level of Janus kinase (JAK)/ signal 
transducer and activator of transcription (STAT) activation [43]. 
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1.2 IV infection: clinical presentation and treatment 
strategies 
1.2.1 Clinical manifestation of uncomplicated IV infection  
Usually, large amounts of influenza viruses are presented in respiratory secretions of infected 
individuals resulting in a direct transmission via coughing and/or sneezing or a contact with 
contaminated items. The incubation period ranges from 1 to 4 days, with an average of about 
48h. Typical influenza disease in adults is characterized by sudden onset of high fever, chills, 
myalgia, headache and fatigue. Subsequent upper respiratory tract symptoms include 
pharyngitis, nasal congestion, rhinitis, non-productive cough and conjunctivitis. Children 
may have prominent nausea, vomiting or abdominal pain and infants may present with a 
sepsis-like syndrome. These signs and symptoms are due to both, the damage at the site of 
virus replication and the systemic response to IAV.   
1.2.2 IAV induced pneumonia and acute lung injury (ALI)  
The most common complication of IAV infection is viral spread to the distal lung, causing 
diffuse alveolar damage resulting in severe consequences for the gas exchange function of the 
respiratory tract. Children under 5 years of age especially younger than 2 years old, elderly 
patients, obese or patients with comorbidities are more prone to develop complications from 
IAV infection and display increased mortality rate [46]. In case of highly pathogenic IV 
infections, as the 1918 pandemic or the 2009 pandemic H1N1 IAV, previously healthy 
patients younger than 60 years of age are more frequently affected [15, 47-51]. Of note, the 
larger risk to develop severe IV infection was observed among pregnant women [47, 52, 53]. 
However, also during seasonal epidemics, previously healthy individuals develop rapidly 
progressing primary viral pneumonia leading to acute respiratory distress syndrome (ARDS) 
and in very severe cases with multiple organ failure resulting in death [54]. Additionally, 
secondary bacterial pneumonia with S. aureus, H. influenzae and predominantly with S. 
pneumoniae was associated with increased mortality [55]. 
Alveolar epithelial damage is due to direct cytolytic effect of IAV and indirect damaging 
effect of an overwhelming and exaggerated host response [1, 5]. Diffuse alveolar damage 
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(DAD) caused by IAV, further histopathological changes in the lung and clinical features of 
IAV-induced acute lung injury (ALI) are similar to those caused by many other pathogens 
causing severe pneumonia. 
a) ALI/ARDS definition 
According to the recent Berlin consensus definition, acute respiratory distress syndrome 
(ARDS) is defined as a severe hypoxaemia refractory to supplement oxygen therapy 
occurring within 72h due to an acute inflammatory lung injury. Bacterial or viral pneumonia 
is the most prevalent cause of ARDS [56, 57]. The acute onset of inflammation in the lower 
compartment of the lung is followed by an increased vascular permeability due to a rapid 
disruption of the microvascular barrier, resulting in accumulation of protein- and 
inflammatory cell-rich edema fluid in the alveoli [58, 59]. ARDS is categorised as mild, 
moderate and severe with typically present bilateral opacities on chest radiograph (Figure 1-
4), pulmonary artery wedge pressure ≤18 mmHg with lack of left atrial hypertension and 
PaO2/FiO2 ratio ≤300mmHg. 
 
Figure 1-4. (A) Chest X-ray images illustrating early ALI, demonstrating patchy infiltrates in the right lower 
lung field and also in the left lower lung field (red arrow). (B) Chest X-ray in the time course of ALI progression 
towards ARDS, which required intubation (white arrow) and mechanical ventilation. The blue arrows represent 
progression of bilateral radiographic infiltrates and dense consolidation in the right upper, right lower, and left 
lower lung fields. Adapted from [58]. 
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b)  Pathology and pathogenesis 
Histophatologically, three phases are recognized during the evolution of ALI/ARDS [57, 58, 
60]. The initial or early phase, so called exudative phase, is characterized by diffuse alveolar 
damage and endothelial injury. It leads to accumulation of protein enriched and highly 
cellular edema. Edema fluid is rich in proteins such as fibrin and causes hyaline membrane 
formation. A variety of mediators boost alveolar endothelial and epithelial permeability, 
amplified by the inflammatory cells and their cytokines (Figure 1-5). The subacute or a 
proliferative phase of ALI can occur from day 5 onwards. It is characterized by persistent 
hypoxaemia, increased dead space ventilation, and reduced lung compliance. During this 
phase some of the edema is being reabsorbed and proliferation of alveolar epithelial type II 
cells (AEC II) and repair signs emerge. This is accompanied by interstitial fibrosis, and 
disruption of capillary function. In some patients these changes can resolve and clinical 
improvement can be observed. In more severe cases ARDS persists beyond 14 days and it 
leads to a chronic or fibrotic phase. This stage results from outspread pulmonary fibrosis and 
loss of the normal lung structure. 
 
Figure 1-5. The schematic picture represents normal alveolus (left) and injured alveolus (right) during 
ALI/ARDS. The left picture shows an intact epithelial-endothelial barrier with healthy alveolar epithelium 
(AEC II, alveolar epithelial type II cells; AEC I, alveolar epithelial type I cells; AM, alveolar macrophage). The 
right picture demonstrates endothelial-epithelial barrier disruption, injury of AEC and alveolar edema, and 
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hyaline membrane formation. Intra-alveolar edema fluid is enriched with various proteins and inflammatory 
cells producing different cytokines. Adapted from [57]. 
The pathogenesis of ALI/ARDS is associated with dysregulated inflammation, inappropriate 
accumulation and activation of leucocytes and platelets, uncontrolled activation of 
coagulation pathways and lung alveolar epithelial-endothelial barrier disruption [58, 61]. 
Ultrastructural injury to alveolar type I cells (AEC I) was identified in patients who had died 
of ARDS [62]. IV induces lung epithelial apoptosis via NS1, PB1-F2 or M2, and a lot of 
signalling pathways, for example mitogen-activated protein kinases (MAPK), are involved in 
apoptosis initiation [45, 63]. Macrophages are excessively recruited from the circulation and 
injurious and pro-apoptotic cytokines are expressed and released from the cells. This 
contributes to extended apoptotic damage including non-infected neighbouring AECs [63, 
64]. Additionally, neutrophils are critical players in the lung injury. They accumulate in the 
lung microvasculature where they get activated and degranulated resulting in release of 
several toxic mediators, such as proteases, reactive oxygen species (ROS), pro-inflammatory 
cytokines or pro-coagulant molecules. This results in increased endothelial permeability and 
loss of normal endothelial barrier function, resulting in impaired gas exchange [57]. Increased 
permeability of lung microvascular barrier is associated with alveolar haemorrhage and 
occurrence of erythrocytes in the alveolar space. 
c) Resolution and repair 
The most important task for survival and recovery from ALI/ARDS is to restore the normal 
physiological function of alveolus. The shift away from pro-inflammatory signaling and 
efficient clearance of inflammatory cells is a crucial point of recovery. It was thought that 
resolution of inflammatory injury occurs primarily due to the passive decline of various pro-
inflammatory mediators [65]. Recent investigations demonstrated a complex class of 
specialized pro-resolving mediators (SPM) such as lipoxins, resolvins, protectins and 
maresins to be actively generated during resolution phase [66, 67]. They have been shown to 
carry both, anti-inflammatory and pro-resolving bioactivities. This leads to tissue damage 
limitation, shortening of resolution time and promotion of healing. Moreover, apoptotic 
neutrophils and other cells are removed by macrophages via efferocytosis. Additionally, 
resident and AM contribute actively to resolution of pulmonary inflammation as they, for 
example, initiate lung tissue repair [68]. Following clearance of the airspace from cells, 
excessive fluid and debris, the damaged alveolar epithelium must be repaired and the 
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epithelial-endothelial barrier function be returned to a basic functional state. Growth factors 
appear to play a major role in repair and resolution of lung injury. Different growth factors, 
such as keratinocyte growth factor (KGF), hepatocyte growth factor (HGF) or epidermal 
growth factor (EGF) promote repair of damaged alveolar epithelium [69-74]. Moreover, 
vascular endothelial growth factor (VEGF), primarily produced by epithelial cells, promotes 
endothelial repair in ALI [61, 75-77]. Endogenous lung stem/progenitor cells showed to self-
renew, proliferate and replace damaged cells by differentiation [65, 78-80], thus promoting 
epithelial barrier repair, eventually guided by newly emerging lung vasculature [65]. At the 
same time as lung epithelial integrity is restored, effective edema fluid transport over the 
epithelium is started, together with restored surfactant secretion.  
1.2.3 IV infection treatment strategies and challenges 
Currently approved antivirals are Amantadine and Rimantidine, sterical M2 ion inhibitors, as 
well as Oseltamivir, Zanamivir, Peramivir or Laninamivir, which bind to the enzymatic 
active site of NA. However, Amantadine and Rimantidine are not recommended for currently 
circulating IV due to high prevalence of resistance [81, 82]. Moreover, recently, H1N1 IAV 
strains resistant to Oseltamivir have been reported [83-86]. Additionally, the approved 
medication is not tested in children less than 2 years of age. Also, the reports of especially 
virulent IAV causing rapid progression of respiratory infection leading to fatalities [54, 87] 
showed that the specific anti-viral therapies might not be enough effective for the treatment 
of complicated IAV pneumonia. 
1.2.4 Therapeutic strategies in IV-induced ARDS 
The significant progress in understanding the pathophysiology of ALI/ARDS has, 
unfortunately, not resulted in any specific treatment of this devastating disease except 
symptomatic intensive care treatments resulting in declined mortality rates from 60-80% to 
30-50% [88, 89] since the ALI/ARDS was initially described in 1967.  
A large number of different pharmacological therapies have been evaluated in Phase II and 
Phase III clinical trials for ALI/ARDS therapy but never resulted in a proof of efficacy of any 
specific treatment strategy, whereas some symptomatic treatments are now standard of care. 
Protective mechanical ventilation strategies proved advantages in survival [90-92]. 
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Restrictive intravenous fluid therapy, nitric oxide (NO) inhalations [90], other pulmonary 
targeted pharmacological therapies, as surfactant instillations [60] and rescue strategies such 
as prone positioning [93, 94] or extracorporeal membrane oxygenation (ECMO) [95, 96] are 
highly recommended to improve patient’s condition in pediatric and/or adult ARDS. Local or 
systemic use of glucocorticoids remains controversial [57, 97, 98], thus not recommended to 
date. Additionally to supportive care, antiviral treatment with NA inhibitors should be started 
as soon as possible [99, 100].  
Unfortunately, despite considerable advances in clinical supporting measurements to treat 
ALI/ARDS, none of the previous mentioned pharmacological therapy methods has proven to 
be highly effective. Furthermore, growing prevalence of drug-resistant IAV strains request a 
necessity to consider and develop new therapeutic approaches.   
1.2.5 Cell therapies 
In terms of promising new therapies, cell therapy methods have been explored as a novel 
treatment approach in ALI/ARDS. This strategy encompasses methods where cells, whether 
endogenous or exogenous, are applied to ameliorate disease progression or in a case when 
regeneration or repair is necessary.  
Stem cells are defined as undifferentiated precursor cells with self-renewal potential and 
ability to differentiate into cells of multiple lineages. They can be classified to pluri- or multi-
potent and adult tissue-derived or embryonic. As embryonic pluripotent stem cells (ESC) 
have potential to form neoplasms due to their ability to proliferate indefinitely without 
differentiation [101, 102] and display immunological incompatibility between donors and 
recipients [103], their application as therapeutics is debatable. Endothelial progenitors (EPCs) 
are an interesting candidates as endothelial damage is a key pathophysiological feature of 
ALI/ARDS [65], but their use is limited, e.g. by the difficulties in their isolation [104].  
Endogenous lung stem cells of mesenchymal or epithelial lineage have been considered for a 
therapeutic application, as they represent an ideal type of stem cells to regenerate injured lung 
[78, 105, 106], however, robust markers for their identification and protocols for expansion 
are still lacking [107, 108]. Similarly, the use of hematopoietic stem cells (HSCs), foetal stem 
cells or induced pluripotent stem cells (iPSCs) need more investigations regarding their 
clinical reliability for ALI/ARDS [104]. Due to the easy accessibility and low 
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immunogenicity, (bone marrow-derived) mesenchymal stem cells (MSCs) have come into 
focus as putative source of cell therapies to treat a variety of different acute and chronic 
diseases. They can be produced under GCP (good clinical practice) conditions to large 
quantities, and have been tested for efficacy in many clinical trials in recent years.   
1.3 Mesenchymal stem cells (MSC) 
1.3.1 Definition and identification 
Mesenchymal stem or stromal cells (MSCs) are adult multipotent endogenous non-
hematopoietic precursor cells with capabilities of high proliferation and self-renewal. MSCs 
were first described in the adherent fraction of bone marrow stroma in 1976 [109, 110], but 
have also been found in multiple anatomical locations, as skeletal muscle, umbilical cord, 
adipose and other tissues [111-130]. Despite a very low prevalence of around 0.001 to 0.1% 
of the total bone marrow nuclear cell pool [131-133], bone marrow derived MSC (BM-MSC) 
is a relatively easy accessible cell fraction. As shown in Figure 1-6, BM-MSC reside in a 
subendothelial position of the outer surface of sinusoids, a characteristic type of blood vessels 
in the bone marrow [134-136]. 
 
Figure 1-6. Schematic picture representing location of MSCs in the bone marrow subendothelial region adapted 
from Bianco et al [136]. HSC, hematopoietic stem cell; EC, endothelial cell; MSC, mesenchymal stem/stromal 
cell. 
Recently, MSC have been reported to differentiate into a variety of cell types both in vivo and 
under proper culture conditions in vitro [137-148] (Figure 1-7). 
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Figure 1-7. Differentiation and self-renewal potential of BM-MSC, adapted from Uccelli et al [137]. 
A consensus paper of International Society of Cellular Therapy defines the minimal criteria 
necessary to identify MSC [149] and standardize the procedures to be used. According to this 
statement, isolated MSCs must be spindle-like cells and adherent to plastic under standard 
culture conditions. Secondly, their phenotype must be confirmed via expression of specific 
markers as CD105 (endoglin), CD73 (known as ecto 5’ nucleotidase) and CD90 (Thy-1). 
MSC must lack expression of CD45 (typical leukocyte marker), CD34 (primitive 
hematopoietic progenitor and endothelial cell marker), CD14 or CD11b (both expressed on 
differentiated myeloid cells), CD79α or CD19 (both B lymphocyte markers) and HLA-class 
II. Finally, these cells should be able to differentiate into adipocytes, osteoblasts and 
chondroblasts under specific culture-differentiating conditions. These guidelines can be 
applied to MSC isolated from human and murine tissues.  
1.3.2 Therapeutic potential of MSC 
The interest in MSC as a very attractive therapeutic approach for ALI/ARDS stems mostly 
from their potential to modulate host immune response to injury and infection and to 
contribute to following repair processes.  
20 
 
a) MSC display a low immunogenicity profile 
Tolerance induction in the periphery is critical to prevent autoimmunity and maintain 
immune homeostasis. MSC demonstrate a low immunogenicity pattern due to constitutive 
low expression of histocompatibility complex (MHC) I and II proteins and lack of T cell co-
stimulatory molecules (CD80 and CD86) [150-157]. Given that, MSC are safe for allogeneic 
transplantation [158, 159]. However, recent observations suggested that the mechanisms of 
action of MSC as “cellular tolerogens” can be far more complex [160] and that MSC might 
be less immunoprivileged as first proposed [161, 162].  
b) MSC are inflammation sensors and stimulate inflammation resolution 
MSC are sensors of inflammation able to acquire anti-inflammatory or pro-inflammatory 
phenotypes, however, the underlying mechanisms are undefined. The beneficial anti-
inflammatory action of administered MSC largely relies on specific production of secretory 
proteins, likely depending on the type of injury and on the microenvironment. MSC can be 
primed by different stimuli and it has been suggested that they can be polarized into distinct 
phenotypes, improving host defense in the context of infection (“MSC1”), or driving 
tolerance, injury resolution and tissue repair (“MSC2”) (Figure 1-8) [163-165].  
 
Figure 1-8. Polarization of MSC into pro-
inflammatory and anti-inflammatory 
phenotypes. (A) Specific factors (high 
levels of IFNγ or TNFα) or direct 
stimulation of toll like receptor 3 (TLR3) 
drive MSC to adopt an immunosuppressive 
and tolerogenic phenotype (MSC2). (B) 
The switch towards a pro-inflammatory 
MSC phenotype (MSC1) is triggered by 
low levels of IFNγ or TNFα. This can be 
driven by activation of TLR4 as well and 
drive presence of activated T cells relevant 
for anti-pathogen host defense. Adapted 
from [163].  
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The switch towards MSC1 or MSC2 depends on levels of soluble factors as IFNγ or TNFα, 
and can also be stimulated via Toll like receptors (TLR) 3 or 4 activation [163, 166-169]. The 
balance between these pathways is crucial for promoting host defense without inducing 
excessive tissue damage and promoting repair. Moreover, recent investigations show that 
MSC conditioning via TLR3 can amplify their trophic factor production and enhance their 
anti-inflammatory potential [167, 169-171]. 
c) Main mechanisms involved in MSC therapeutic potential: paracrine action 
via soluble factors 
A growing number of studies revealed different MSC and host tissue interaction pathways, 
e.g., mitochondrial transfer [172, 173], direct interactions with the host immune system cells 
[157, 161, 174-178]. However, the most robust evidence supported MSC mechanism of 
action is attributed to their paracrine effect via soluble factors. The proteomic analysis of the 
human MSC secretome revealed their capacity to produce a wide range of proteins with 
trophic (anti-apoptotic, stimulation of mitosis, proliferation and differentiation, angiogenic), 
immunomodulatory, anti-scarring and chemoattractant activities (Figure 1-9) [179, 180].    
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Figure 1-9. Paracrine effects of cultured MSCs. They secrete a broad range of bioactive molecules and now it is 
attributed to a therapeutic effect of these cells. The main mechanisms by which MSC achieve their therapeutic 
potential can be divided into six main categories: immunomodulation, anti-apoptotic, angiogenesis, growth and 
differentiation support of local stem/progenitor cells, snit-scarring and chemoattraction. Secretion of PGE-2 
(prostaglandin E2), HLA-G5 (human leukocyte antigen G 5), iNOS (inducible nitric oxide synthase), HGF 
(hepatocyte growth factor), IDO (indoleamine 2,3-dioxygenase), TGF-β (tumor growth factor b), LIF (leukemia 
inhibitory factor) and IL-10 (interleukin 10) contributes to MSC immunomodulatory effect. MSC limit 
apoptosis principally by secreting VEGF (vascular endothelial growth factor), HGF, IGF-1 (insulin-like growth 
factor 1), Sta-1 (stanniocalcin-1), TGF-β and GM-CSF (granulocyte macrophage colony-stimulating factor). 
Moreover, local angiogenesis promoting effect is achieved by secreting extracellular matrix molecules, such as 
VEGF, IGF-1, PIGF (placental growth factor), MCP-1 (monocyte chemoattractant protein 1), bFGF (basic 
fibroblast growth factor) and Il-6. Additionally, mitosis and tissue progenitor/stem cells are stimulated via 
production of SCF (stem cell factor), LIF, M-CSF (macrophage colony-stimulating factor), SDF-1(stromal-
derived factor 1) and angiopoietin-1. Finally, a group at least of 15 chemokines are constitutively expressed by 
cultured MSC. Adapted from [181].  
As an example, therapeutically applied MSC secrete VEGF, HGF and insulin-like growth 
factor 1 (IGF-1) or stanniocalcin-1 (Sta-1), reducing tissue apoptosis levels in kidney and 
myocardial injury models [182-186] and also acting as anti-fibrotic molecules [187]. MSC-
derived KGF and VEGF, released under defined injury-related conditions, were shown to 
contribute to tissue regeneration and repair process [188-191] and consequently linked to 
their anti-apoptotic potential [132, 192, 193]. Moreover, MSC secretory products are capable 
to directly induce growth, propagation and differentiation of local stem and progenitor cells 
and contribute to repair and regeneration of various tissues [194, 195].  
d) MSC in ALI/ARDS models 
Several studies have shown that BM-MSC may have therapeutic application in various 
clinical disorders, including sepsis, myocardial infarction, acute renal failure and others [158, 
160, 192, 196-211]. Steadily increasing numbers of investigations demonstrate efficacy of 
application in a growing spectrum of lung injury in vivo models [164, 172, 193, 209, 211-
239]. Although, the mechanisms of MSC´s beneficial action in these models is not fully 
understood, many studies indicate that MSC secreted soluble factors are involved and 
important in ameliorating acute and chronic lung injury. Initially, bleomycin-mediated ALI 
was used to address BM-MSC´s therapeutic potential. Despite low engraftment levels in the 
lung, systemic administration of BM-MSC showed to protect lung tissue from bleomycin 
induced lung damage and contributed to lung repair [230, 232]. The anti-fibrotic and anti-
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inflammatory effects were found to be mediated by interleukin 1 receptor antagonist (IL1RN) 
[193].  
To examine MSC effect in pathogen-induced ALI, MSC were applied in Escherichia coli 
endotoxin or live bacteria induced ALI. Intrapulmonary BM-MSC application increased mice 
survival, improved lung injury and showed downregulated pro-inflammatory responses to 
endotoxin via lowering levels of TNFα and MIP-2, and increasing levels of IL-10, which has 
lung-protective effect [212]. Subsequently, the same group demonstrated that, following the 
E. coli endotoxin-induced ALI, treatment with human MSC or MSC-derived conditioned 
medium (CM) reduced lung edema, and improved lung endothelial barrier function. Impaired 
alveolar fluid clearance (AFC) and disrupted epithelial-endothelial barrier function is very 
common in patients with ALI/ARDS. The level of AFC impairment is a significant 
prognostic value to determine patient morbidity and mortality [59, 240]. Increased 
endothelial-epithelial barrier permeability and insufficient AFC leads to accumulation of 
protein rich edema fluid in the alveoli. KGF secreted by BM-MSC was attributed a beneficial 
effect to reduce edema formation [215]. Together with angiopoietin-1 (Ang1) it was shown to 
contribute to edema resolution and reduce bronchoalveolar lavage protein levels [164, 191, 
241]. In addition, several other experimental studies confirmed that MSC application 
decreased endothelial permeability and had a protective effect against inflammatory 
disruption of barrier function [209, 210, 242, 243]. Further endotoxin-mediated ALI studies 
confirmed therapeutic effect of BM-MSC by showing reduced pulmonary inflammation, 
injury and edema [213], improved vascular permeability [244], suppressed systemic response 
to endotoxin via decreased levels of TNF-α and IL-1β [231, 244] and simultaneously 
increased levels of IL-10 [244] after systemic infusion of BM-MSC. Additionally, Ang-1 
transfected MSC reduced severity of LPS induced ALI [164, 214]. Moreover, MSC treatment 
improved survival, enhanced bacterial clearance, upregulated antimicrobial protein lipocalin 
2 levels [234] and decreased bacterial growth [191, 209] in live bacteria injured lung. 
Furthermore, MSC produced and secreted antimicrobial peptide, human cathelicidin hCAP-
18/LL-37 in pneumonia caused by Gram-negative bacteria (E.coli and P.aeruginosa). Jointly, 
this antibacterial effect and immuno-modulatory properties of MSC were proved in several 
bacterial sepsis models demonstrating reprogramming of endogenous macrophages resulting 
in increased IL-10 production [211].  
BM-MSC therapeutic mechanism in ALI/ARDS is summarized and presented in the picture 
below (Figure 1-10). 
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Figure 1-10. The beneficial actions of intravenously or intra-tracheally installed MSC in ARDS. The 
modulatory effects include: exertion of anti-inflammatory effects on host tissue, reduction of the permeability of 
the alveolar epithelial-endothelial membrane, improvement of alveolar fluid clearance, improved macrophage, 
monocyte and neutrophil phagocytic activity, exertion of anti-apoptotic effect on host cells, antimicrobial effect. 
MSC might modulate tissue repair through direct mitochondrial transfer or via exosomes. ARDS, acute 
respiratory distress syndrome; MSC, mesenchymal stem cell; AEC I, alveolar epithelial cell type I; AEC II, 
alveolar epithelial cell type II; AM, alveolar macrophage; FGF7, fibroblast growth factor 7; Ang-1, angiopoetin-
1; Il-1ra, interleukin 1 receptor a; TSG-6, TNF-stimulated gene 6; LL-37, antimicrobial peptide. Adapted from 
[245].  
e) MSC paracrine support via extracellular vesicles (EVs) 
A relatively new discovery is that the beneficial effect of MSC is mediated via the release of 
various particles, such as extracellular vesicles. Extracellular vesicles (EVs) are generally 
referred as ectosomes or microparticles, and include apoptotic bodies (50 – 5000nm), 
microvesicles (MV) (100 – 1000nm) and exosomes. Exosomes have received much attention 
being a subclass of (nano) vesicles sized 30-100nm. Their membranes are enriched with 
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cholesterol, sphingomyelin, ceramide and lipid rafts. These EV contain proteins, lipids, 
nucleic acids and mRNAs and miRNAs [246-252] (Figure 1-11). Exosomes are derived from 
the late endosomes or multi-vesicular bodies (MVB). Once secreted, exosomes can either be 
endocytosed after binding to recipient cell or stay in biological fluids [250]. These nano 
vesicles were shown to be released by various cell types [253-258]. Most exosomes have an 
evolutionary conserved set of surface proteins like tetraspanins (CD63, CD81, and CD9), 
Alix or Tsg101, but also a specific set of proteins reflecting their cellular source (Figure 9). 
The internal EV membrane is enriched in lipids [259]. The lipid composition of exosomes is 
distinct from that of the cell origin, but is characteristic to a specific cell type.  
 
Figure 1-11. Schematic picture of exosome and some proteins and lipids present in it. Tetraspanins (CD9, 
CD63, CD81, CD82) and heat schock proteins (Hsp) such as Hsp90 and Hsc70 are enriched in exosomes. 
Phospholipidases are activated by GTPases (Rab, Rap, Ran, RhoA, Arf) and are regulated by aldolase, casein 
kinase II, and Hsp/Hsc70. The major phospholipids are present in exosomes but in distinct proportions as 
compared to parent cells, as well as lipid rafts. LBPA, lysobiphosphatidic acid; PS, phosphatidylserine; PI, 
phosphatidylinositol; PC, phoshatidylcholine; PE, phosphatidylethanolamine; DG, diacylalkylglycerols; SM, 
sphyngomyelin; Rab, a member of Ras superfamily of monomeric G proteins; Hsp, heat schock protein. 
Adapted from [260].  
The MSC microvesicle genome analysis revealed 239 unique transcripts for genes that were 
involved in cell differentiation, transcription, proliferation and immune regulation [261]. 
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Moreover, 730 proteins for cell proliferation, adhesion and migration were identified in a 
proteomic analysis of MV derived from human MSC [262]. Consequently, recent studies 
showed exosome contribution to immune response [263], exosome function as mediators of 
cell-cell communication [264], exosomes‘ beneficial effect in cardiac repair [252, 265, 266] 
and neurological recovery potential [252, 267]. An intra-tracheal MSC MV application in 
endotoxin-mediated lung injury displayed a potential benefit equal to the cell administration 
and reduced lung inflammation and prevented edema formation [228]. Another study 
demonstrated that MSC treated LPS-injured mice transferred mitochondria-containing MV to 
AECs via the gap junctions [172]. These data supported the hypothesis, that MSC derived 
exosomes could contribute to lung repair.  
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2. Aims of this work 
IAV induced ARDS is associated with 60% lethality and has been frequently observed upon 
H5N1 and pandemic H1N1 IV infections [54, 87, 268]. Antiviral therapies are only effective 
in the very beginning of IV infection, and specific treatment methods for IV-induced ARDS 
are still lacking. Recently, MSC, multi-potent stromal cells with anti-inflammatory and 
regenerative potential [210, 269, 270], were attributed a beneficial role in acute and chronic 
lung injury [212, 221, 225, 230, 235, 271], suggesting MSC delivery to be a promising 
treatment strategy in IV-induced ARDS.  
The first aim of the presented work was to isolate and characterize primary bone marrow 
derived MSC from healthy wild type (wt) mice. As the putative beneficial role of MSC in 
IAV-induced lung injury has not been studied so far, the second aim of presented thesis was 
to address their potential and mode of action in in vitro co-culture models with IAV-infected 
primary alveolar epithelial cells (AECs). Further, the impact of their intra-tracheal application 
was analysed in in vivo IAV induced lung injury in mice.  
 
:  
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3. Materials and methods 
3.1 Mice strains 
Wildtype C57BL/6N mice (wt) were purchased from Charles River Laboratories (Germany). 
Gt(ROSA)26Sor 
tm4(ACTB-tdTomato,-EGFP)Luo
/J (mT/mG) [272] mice expressing a red 
fluorochrome (tdtomato) on all cells were purchased from Jackson Laboratory (USA), ifnar-/- 
[273] were provided by U. Kalinke (Paul-Ehrlich Institute, Langen, Germany). Mice were 
housed and bread under specific pathogen-free conditions (SPF) at the Justus-Liebig 
University of Giessen. For in vivo experiments 8 to 12 weeks old wt and ifnar-/- mice were 
monitored 1 to 2 times per day.  
3.2 IAV strain 
A/Puerto Rico/8/1934 H1N1 (PR/8) mouse adapted influenza A virus was used for all 
experiments, propagated on MDCK (Madin Darby Canine Kidney) cells and virus titres were 
regularly checked by plaque assay. 
3.3 Primary cells and cell lines 
3.3.1 Cell lines 
Mesenchymal stem cells (MSC, Cyagen) and 3T3 (NIH) cells were cultured in cell culture 
flasks in adequate media (see table below) at 37°C and 5% CO2. For passaging, cells were 
washed with PBS (PAN-BIOTECH) and then detached and singularized with Stem-
Pro®Accutase® (TermoFischer Scientific). For freezing, MSCs were kept in NCR Protein-
Free Cryopreservation Medium (Cyagen Biosciences) and 3T3 in 10% DMSO in FCS (Fetal 
Calf Serum, Life Technologies). 
Cells Origin Culture medium 
MSC, 
Cyagen  
C57Bl/6N Mouse Bone 
Marrow Mesenchymal Stem 
Cells 
Strain–OriCell™ Mouse Mesenchymal Stem 
cells Growth Medium (Cyagen Biosciences) 
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NIH/3T3 Mouse embryonic fibroblasts DMEM (Life Technologies), 10%FCS + 
1%Penicillin/Streptomycin (P/S, Sigma)) + 
1%L-Glutamine (Sigma) 
3.3.2 Primary Murine Alveolar Epithelial Cells (AECs) 
AEC were isolated as described by Corti et al [274]. Briefly, mice were sacrificed; lungs 
were perfused with sterile HBSS (Gibco) via a 26-gauge cannula inserted into the right 
ventricle. Then sterile dispase was instilled into the lung. Lungs and trachea were removed 
and incubated in dispase for 40min at room temperature (RT). After incubation, heart, trachea 
and large bronchi were removed. Remaining lung tissue was processed in 
DMEM/2.5%HEPES (Biochrom) plus 0.01%DNAse (Serva) for homogenisation using 
gentleMACS Dissociator (Milteny Biotec). Lung tissue was then incubated for 5min at RT by 
gentle rotation. After incubation, cells were filtered, washed, resuspended in DMEM/2.5% 
HEPES and counted. Next, cells were incubated with biotinylated anti-mouse CD45, 
CD16/32, CD31 antibodies (BD Pharmingen) for 30min at 37°C to exclude remaining 
endothelial cells and leukocytes. The amounts of antibodies were calculated as following: 
 
After incubation, cells were washed and mixed with streptavidin-linked magnetic beads 
(Invitrogen) prewashed thrice with PBS. The mixture was incubated for 30min RT with 
gentle rocking. The amount of magnetic beads was calculated as follows:  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
1.000.000
3
× 50 = 𝑚𝑎𝑔𝑛𝑒𝑡𝑖𝑐 𝑏𝑒𝑎𝑑𝑠 (µ𝑙) 
Magnetic separation was performed at RT. The remaining suspension was washed and cells 
were resuspended in mAEC (murine alveolar epithelial cell) medium. Freshly isolated 
mAECs were stained for EpCAM (epithelial cell adhesion molecule) and pro-surfactant 
protein C (pro-SPC) and purity was analysed by flow cytometry (see Flow cytometry 
section). Only cell suspensions with a purity ≥90% were used for further experiments as 
described elsewhere. Cell viability was tested by trypan blue (Gibco) staining and was ≥95%. 
𝑪𝑫𝟒𝟓(µ𝑙) =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
1.000.000
× 0.9 𝑪𝑫𝟏𝟔 𝟑𝟐⁄ (µ𝑙) =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
1.000.000
× 0.675 𝑪𝑫𝟑𝟏(µ𝑙) =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
1.000.000
× 0.4 
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3.3.3 Primary Murine Bone Marrow Mesenchymal Stem cells (BM-
MSC) 
Wt and mTmG mice were used for BM-MSC isolation. BM-MSC were isolated following a 
protocol adapted from Houlihan et al [131]. 8-12-week-old mice were sacrificed by cervical 
dislocation and isoflurane inhalation. Mice were disinfected with 70% (vol/vol) ethanol and 
limbs (tibias, femurs, hips and humeri) were freed from skin and hair covering. Bones were 
dissected from adherent muscle by blunt dissection. Dissected bones were carefully cleaned 
using gauze swabs to remove remaining muscle tissue. Cleaned bones were stored in 30ml 
ice-cold PBS. Next, they were washed in fresh ice-cold PBS thrice by vigorous shaking. 
Then, bones were gently crushed using sterile pestle and mortar avoiding multiple crushes per 
bone. The crushed bones’ fragments were cut into tiny pieces with sterile scissors. The paste 
like mass was stored in 1-2ml HBSS+ and then three times washed with 10ml HBSS+ (see 
table below) per wash. Bone mass was then collected into a 50ml conical tube with 20ml 
preheated MSCs Medium+0.2% (wt/vol) collagenase A (Roche Diagnostics, DE) and 
incubated for 90min at 37°C by gentle shaking. After incubation cell suspension was filtered 
through a 70µm cell strainer in a conical tube and it was placed on ice to quench collagenase 
activity. The remaining bone fragments were placed in the mortar and crushed by gentle 
tapping to avoid too much damage to the BM-MSC pool. The bone mass was several times 
washed with HBSS+ (see table below) and cells were washed out into solution by gentle 
pipetting. The liquid was then filtered and centrifuged at 500g for 10min at 4°C. The pellet 
was erylysed with 1-2ml sterile ice-cold water for 6s. The reaction was quenched 
immediately after the lysis adding 1-2ml PBS2x. The suspension was again filtered through 
the 70µm cell strainer and then centrifuged in a precooled centrifuge at 500g for 5min. After 
the second centrifugation step, cell pellet was resuspended in HBSS+ and counted. Count and 
viability was assessed by trypan blue staining. Succeedingly, cells were prepared for FACS 
analysis (See Flow cytometry and cell sorting). Samples were stained with an antibody mix 
(CD45, TER119, Sca-1, PDGFRα/CD140α). Cell purity was measured after each sort, and 
was between 90-95%. Sorted cells were then seeded for further expansion and incubated in 
37° and 5%CO2. Medium was first changed after 3-4 days and then every 2-3 days. For 
passaging, cells were twice washed with PBS and then detached and singularized with Stem-
Pro®Accutase®. Passages 8-12 were used for further experiments. 
 
31 
 
Reagents Composition 
HBSS+ Hank`s Balanced salt solution + 2%(vol/vol) FCS + 
1%(vol/vol)P/S + 10mM Hepes 
MSCs Medium DMEM low Glucose+Glutamax (Gibco) + 10%(vol/vol) 
FCS + 1%(vol/vol)P/S 
PBS2x Double-strength Phosphate buffered solution (PBS) + 4% 
(vol/vol) FCS 
 
3.4 BM-MSC Characterization and differentiation 
BM-MSCs were characterized at passage 5 to 18 following the Consensus Protocol proposed 
by the International Society for Cellular Therapy [149].  
To examine MSC surface antigen expression, BM-MSC were stained with anti-mouse 
antibodies against CD105, CD73, CD90.2, PDGRFα, Sca-1, CD44, CD29, CD117, CD45, 
CD19, CD11b, CD31, CD34, TER119 and appropriate isotype controls (see the table in Flow 
cytometry and cell sorting). 
 
For differentiation experiments cells were seeded in 8-well chamber slides (Thermo 
Scientific). Adipogenic differentiation was performed following manufacturer’s instructions. 
Confluent culture was incubated in adipogenic induction medium (Adipogenic Induction 
SingleQuots®, Lonza) for 4 days and then replaced with adipogenic maintenance medium 
(Adipogenic Maintenance SingleQuots®, Lonza) for 3 days. After two cycles, cells were 
washed and then fixed. Thereafter, fixed cells were stained with Oil-red O and then slides 
were analysed by light microscopy.  
 
For osteogenic differentiation, a sub-confluent BM-MSC culture was used. Samples were 
cultured in osteogenic medium (Osteogenic SingleQuots®, Lonza) for 14 days. Next, they 
were washed and fixed. After fixation, cells were stained with Alizarin Red Staining Solution 
(Sigma Aldrich) and then analysed by light microscopy.  
 
For chondrogenic differentiation, confluent cells were cultured in chondrogenic maintenance 
medium (Chondrogenic SingleQuots®, Lonza) supplemented with TGF-β3 (10ng/ml; Lonza) 
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and BMP-6 (500ng/ml; R&D Systems) for at least 21 days. Thereafter, cells were washed and 
fixed. Samples were stained with 1% (wt/vol) Alcian Blue Staining solution and incubated 
over night at 37°C. The next day destaining solution consisting of 98-100% Ethanol and 98-
100% Acetic Acid (ratio 3:2) was added, followed by several washing steps in PBS. Then, 
slides were submitted to light microscopy analysis.  
3.5 BM-MSC derived exosomes 
3.5.1 Isolation 
The BM-MSC conditioned medium (CM) was collected daily and frozen in -20°C. 
Dynabeads® Biotin Binder (Invitrogen) were washed 3 times with PBS. Washed beads were 
incubated with CD9 and CD81 biotinylated antibodies (Biolegend) for 45min at RT in PBS + 
0.1% exosome free FCS (SBI) with gentle tilting and rotation. The tubes were placed on a 
magnet for 1min and the supernatant was discarded. The antibody-coated beads were then 3-5 
times washed with PBS+0.1% exosome free FCS. The fresh CM or unfrozen samples were 
filtered through 0.2μm filters and mixed with pre-coated beads. Next, the mix was incubated 
for 24h at 4°C by gentle rotation. After incubation, beads were collected with a magnet for 
≤15min RT (Figure 3-1). Collected beads were washed thrice with PBS+0.1% of exosome 
free FCS, discarding the supernatant each time.  
 
Figure 3-1. Exosome isolation protocole.  
Add mixture of 
Biotinylated antibodies 
(CD81, CD9) 
Add Dynabeads® 
biotin binder 
Wash thrice Wash thrice Incubate Incubate 
overnight 
-Add collected CM 
-Mix with coated 
antibodies 
-Collect beads with 
the magnet 
-Wash 
FACS 
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3.5.2 Exosome characterization 
Coupled beads were resuspended in PBS+ 0.1% exosome free FCS and centrifuged for 5min 
at 3000rpm at 4°C. Probes were then stained for different surface markers and their isotypes 
(see table in section Flow cytometry and cell sorting) and analysed by FACS. Exosome count 
was determined by FACS analysis using the following formula: 
Count of exosomes =
No of events in region containing exo
No of events in absolute count bead reagion
 ×
No of beads per test
Test volume (µl)
 
Bead saturation was defined by serial dilutions.  
3.6 In vivo experiments and sample processing 
3.6.1 Intra-tracheal IAV infection and cell application 
For in vivo IAV infection or cell application after infection, animals were inoculated with 
Atropine sulphate (concentration of 0.05mg/kg) subcutaneously to prevent bradycardia and 
reduce the production of salivary and bronchial secretion to minimise the risk of airway 
obstruction. Mice were subjected to an intraperitoneal Xylazine hydrochloride (concentration 
of 16mg/kg) and Ketamine hydrochloride (100mg/kg) anaesthesia in 0.1ml/10g of body 
weight; or they were sedated via isoflurane inhalation. During the anaesthesia, all animals 
were kept warm on a heating plate to maintain a stable body temperature. The depth of 
anaesthesia was monitored testing pedal withdrawal reflex. After sufficient depth of 
anaesthesia was reached, mice were placed supine on the intubation stand. The upper incisors 
were secured with a fixed rounded rubber loop following fixation of the lower extremities. 
The stand was rotated to a 45° angle and, using a cotton swab, the tongue was rolled out. An 
intubation guide wire with endotracheal tube was introduced from the side of the mouth and 
advanced through the vocal chords into the trachea. The endotracheal tube was then advanced 
over the guide wire, which was immediately withdrawn. Intubation was confirmed by brief 
occlusion of the tube while observing the change in thoracic respiratory movements. Using a 
Hamilton syringe, mice were inoculated with 500pfu (plaque forming units) of PR/8 diluted 
in 40µl sterile PBS. In cell application experiments, PBS or 250 000 3T3 or primary wt BM-
MSC diluted in 40µl sterile PBS or mTmG BM-MSC for MSC trafficking/engraftment 
studies were applied intra-tracheally. After the installation, mice were monitored on the 
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heating plate until complete recovery. Mice were then monitored 1-2 times per day until the 
end of the experiment. 
3.6.2 Collection of Bronchoalveolar Lavage Fluid (BALF) 
Mice were sacrificed as mentioned before. A small tracheal incision was made and it was 
cannulated by a 21-gauge cannula. Consecutive instillations and collection of 300, 400 and 
500µl of ice-cold 2mM EDTA/PBS were performed. Subsequently, BAL collection was 
completed performing installation-collection cycles of 500µl 2nM EDTA/PBS until the final 
volume of 4ml was reached. Both BAL fractions were then centrifuged at 1400rpm 10min at 
4°C. The supernatant of the first BAL fraction was divided into collection tubes for further 
cytokine quantification or alveolar leakage determination. The supernatant of the second 
BAL fraction was discarded and cells from both fractions were pooled and further analysed 
by FACS or microscopy.  
3.6.3 Preparation of Lung Cell Homogenate (LH) 
LH was prepared following the procedure steps as described in the section Primary Murine 
Alveolar Epithelial Cells (AEC). After filtration and washing steps, cells were resuspended in 
MACS buffer (1x Phosphate buffered solution + 7.5% (vol/vol) EDTA (Biochrom) + 2% 
(vol/vol) FCS) and submitted for flow cytometric analysis or further isolated via FACS-based 
cell sorting. 
3.6.4 Lung permeability assay 
To determine alveolar albumin leakage as determinant of lung barrier function loss, FITC-
labelled albumin (1mg) diluted in 100µl of sterile NaCl 0.9% was injected intravenously into 
the tail vein. After 45min, mice were sacrificed with an overdose of isoflurane and the 
abdominal cavity was opened. Blood was drawn from the inferior vena cava with a 23-gauge 
cannula connected to a 1ml syringe, and immediately transferred into a 1.5ml collection tube. 
The BALF was collected as described before (see section Collection of Bronchoalveolar 
Lavage Fluid). Blood samples were incubated for 3h at RT until coagulation occurred and 
then centrifugated at 4000rpm 15min RT. Serum supernatant was collected thereafter. BALF 
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and serum (the latter 1:100 diluted in PBS) were tested for FITC fluorescence and compared 
with standard samples (serial dilutions 1:10 in PBS). These measurements were performed 
using a fluorescence spectrophotometer (FL 880 microplate fluorescence reader, Bio-Tek 
Instruments, France) operating at 488nm absorbance and 525±20nm emission wavelengths. 
Fluorescence signals of concentrated BALF samples to fluorescence signals of 1:100 diluted 
serum samples are defined as lung permeability index (LPI) and expressed as arbitrary units 
(AU). 
3.6.5 Histological assessment of the lung 
Mice were sacrificed as mentioned before. Lungs were perfused via the right ventricle with 
sterile HBSS. The trachea was cannulated, 1.5ml of 4% of paraformaldehyde (PFA) was 
slowly instilled and the trachea was fixed with a ligature after removing the cannula. The 
lungs were transferred into 4% PFA solution where they were incubated for 24h at 4°C. 
Then, lungs were embedded in paraffin (Leica ASP200S). Thereafter, 3-5µm thick tissue 
sections were cut, put on slides and kept at RT until staining. Tissue cuts were first 
deparaffinised by the following procedure: Xylene 5min (twice), 100% Ethanol (EtOH) 30sec 
(twice), 96%, EtOH 30s, 96% EtOH 30s, 70% EtOH 30s and 70% EtOH 30s. Then, slides 
were stained with haematoxylin and eosin as follows: Haematoxylin 3min, 0.1% HCl 2sec, 
H2O 5min, Eosin G solution 3min, H2O 30s, 70% EtOH 30s, 90% EtOH 30s, 100% EtOH 
30s (twice), Xylene 5min (twice). 
For preparation of cryo-slices, murine lungs were perfused with PBS and intra-tracheally 
filled with 1.5ml TissueTek (Sakura) diluted in PBS (ratio 1:1). The trachea was then fixed 
with a ligature and the cannula was removed. Lungs were embedded in TissueTek diluted in 
PBS (ratio 1:1) and snap-frozen in liquid nitrogen. Cryo-slices of 4-5 µm thickness were 
prepared using a Leica CM1850 UV cryotome. Cryo-slices were stored at -80°C. Thereafter, 
they were air-dried and fixed in Methanol and Acetone (ratio 1:1) for 3min RT. Then, fixed 
cryo-slices were twice washed with distilled water (dH2O). After washing, they were stained 
with DAPI (Sigma-Aldrich) for 5min RT and subsequently washed with dH2O. After 
mounting procedure (Fluoromount™, Sigma-Aldrich), slides were submitted for microscopic 
analysis.  
All slides were analysed with Leica DM 200 microscope and ImageJ software.  
36 
 
3.7 In vitro IAV infection and cell culture assays 
3.7.1 AEC culture and infection 
Isolated primary cells or cell lines were cultured on transwells (12-well, Costar) for five days. 
To achieve the indicated MOI (multiplicity of infection) of the virus inoculum, virus stock 
solution (PR/8) was diluted in PBS supplemented with 0.2% of BSA (bovine serum albumin).  
Prior to the infection, cells were washed with PBS, virus dilution was applied and then 
samples were incubated for 1h at 37°C at 5% CO2. Cells were then washed and placed into 
infection medium containing 0.2% BSA, 100U penicillin/ml, 0.1mg streptomycin/ml and 2 
μg/ml trypsin TPCK (PAA). Infected cells were kept at 37°C 5%CO2 for the indicated time 
periods. 
3.7.2 AEC co-culture with BM-MSC, 3T3 cells or BM-MSC-derived 
conditioned medium (CM) 
For co-culture experiments, 60000 primary mBM-MSC or 3T3 cells were seeded at the 
bottom of transwells two days prior to AEC infection. After 24h inoculation with PR/8, 
bottom seeded cells were combined with AECs seeded on transwells (Figure 3-2).   
 
Figure 3-2. AEC co-culture model with BM-MSC or 3T3 control fibroblasts. AEC, alveolar epithelial cells; 
BM-MSC, bone marrow derived mesenchymal stem cells; 3T3, embryonic fibroblasts; IV, influenza virus; 
MOI, multiplicity of infection. 
BM-MSC derived CM was collected one day after the BM-MSC had been co-incubated with 
PR/8-infected AEC and then incubated with PR/8-infected AEC in transwells (Figure 3-3). 
Cells were collected at indicated time points and used for further experiments. 
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Figure 3-3. AEC co-culture model with conditioned medium (CM) of BM-MSC. AEC, alveolar epithelial cells; 
BM-MSC, bone marrow derived mesenchymal stem cells; IV, influenza virus; MOI, multiplicity of infection. 
3.7.3 BM-MSC priming 
For priming experiments, BM-MSCs were seeded two days before AEC infection with PR/8. 
One day before infection, cells were washed twice with PBS and incubated for indicated time 
points with stimuli (TLR3, 7/8 and RIG-I ligands; cytokines; see table below) diluted in MSC 
medium. After incubation, supernatant was discarded and cells were thoroughly washed 
thrice with PBS and co-cultured with mock or PR/8-infected AEC for 24h at 37°C 5%CO2. 
AECs were detached and submitted to FACS analysis, and culture supernatants were used for 
protein analysis. 
3.8 Analysis of gene expression 
3.8.1 RNA isolation and cDNA synthesis 
RNA isolation was performed following manufacturer’s instructions (RNeasy Kit, Qiagen). 
Briefly, cells were washed with PBS and then lysed with 350μl RLT buffer. Thereafter, 350μl 
of ethanol was added and RNA was precipitated, bound to a silica membrane, washed and 
eluted in small volumes. RNA concentration was measured with Nanovue Plus (GE 
Healthcare). cDNA synthesis was performed using recombinant Taq DNA polymerase 
(Invitrogen) and a thermocycler (PeqSTAR thermocycler (Peqlab, Erlangern (DE)) following 
manufacturer’s instructions (Applied Bioscience). Briefly, 250ng of isolated RNA with dH2O 
in a total volume of 13.5μl were heated up to 70°C for 5min and then samples were put on ice 
Chemical Function Concentration Company 
Poly (I:C) TLR (Toll like receptor) 3 
agonist 
0.5-100 µg/ml Tocris 
R848 TLR 7/8 agonist 10-100 ng/ml InvivoGen 
5′ppp-dsRNA RIG-I agonist 0.5-1 µg/ml InvivoGen 
Recombinant protein Concentration Company 
TNFα, mouse 10-200 ng/ml R&D systems  
IFNβ, mouse  0.1, 05 ng/ml R&D systems  
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for 3-5min. Thereafter, 11.5μl of PCR Master Mix (with reverse transcriptase) was added and 
samples were kept at 37°C for 1h. Reverse transcriptase was inactivated by heating up to 
95°C for 5min. 
3.8.2 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was performed with Power SYBR Green® (ThermoFisher) following the 
manufacturer’s instructions. RPS18 (40S ribosomal protein S18) expression served as 
normalization control. Data are presented as fold change of gene expression over control and 
the formula is the following: 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 2−∆/(∆𝐶𝑡) 
Where ΔCt=ΔCt target – ΔCt reference (RPS18), and Δ(ΔCt)=ΔCt condition – ΔCt control 
The primers used in qRT-PCR are represented in the table below.  
Primer Sequence 
 Forward 5’3’ Reverse 5’3’ 
RPS18 CCGCCATGTCTCTAGTGATCC TTGGTGAGGTCGATGTCTGC 
VEGF CACCATGCCAAGTGGTCCC GTCCACCAGGGTCTCAATCG 
HGF GGGCTGAAAAGATTGGATCA TCGAACAAAAATACCAGGACG 
FGF10 CCATGAACAAGAAGGGGAAA CCATTGTGCTGCCAGTTAAA 
FGF7 TCGCACCCAGTGGTACCTG ACTGCCACGGTCCTGATTTC 
IFNβ GTTACACTGCCTTTGCCA GTGGAGTTCATCCAGGAGACG 
IFNa1 GCATCTACAAGACCCACAATGGC TGTCAAGGCCCTCTTGTTCCC 
GM-CSF GAAGCATGTAGAGGCCATCA GAATATCTTCAGGCGGGTCT 
STC GCCTGATGGAGAAGATCGGG GTGCGTTTGATGTGTGAGGG 
Wnt5a GCAGGACCTGGTCTACAT ACTTGCAATGACAGCGTT 
Melting curve analysis was performed to confirm the exclusive amplification of the 
expected PCR product. 
3.8.3 Microarray experiments 
For microarray experiments, AEC were lysed in lysis buffer (Qiagen kit). The further 
procedure and analysis was performed by J. Wilhem and S. Ziegler (AG Dr. Jochen Wilhelm, 
Giessen) using the Ovation PicoSL WTA System V2 (NuGEN) for cDNA amplification, the 
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QIAquick PCR Purification Kit (Qiagen) for cDNA purification and SureTag DNA Labeling 
Kit (Agilent) for cDNA labeling. After the purification and labeling, cDNA concentration 
was measured with the NanoDrop. Labeled targets were hybridized to Agilent Dual-mode 
Gene expression arrays. Microarray processing was continued according the manufactures 
instructions (NuGEN).  
Gene Ontology (GO) enrichment analysis was performed and provided by Dr. J. Wilhelm. 
Next, each probe set was statistically tested using ANOVA, and the resultant p values were 
adjusted for multiple testing. Hierarchical clustering and heatmap visualization of Z score 
normalized data for complete data or select genes were performed. Further, gene expressions 
were ranked by average fold change and t-statistic, and subsequently summarized using 
volcano plots. Volcano plots represent the negative log10-transformed p-values from the gene-
specific t test against the log2 fold change. Pathway annotation was taken from Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) database package. Only pathways with >3 
genes were considered. The tests were performed based on the t-statistics including both up- 
and downregulated genes.  
3.9 Flow cytometry and cell sorting 
Multicolor flow cytometry analysis was performed with a 4 laser-equipped LSR Fortessa 
FACS analyser using DIVA software (BD Bioscience). Cell sorting was performed with a 4 
laser-equipped FACS ARIA III (BD Bioscience).  
For flow cytometry analysis 1-5x10
5
 cells were resuspended in FACS buffer (PBS, 7.4% 
EDTA, 0.5% FCS pH 7.2, 0.01% Na
+
Azide (Merck)). Cells were then pelleted by 
centrifugation at 1200rpm 3min at 4°C. Unspecific antibody binding was blocked with 10µl 
Sandoglobulin® (Novartis). For intracellular staining, permeabilization was performed using 
0.2% saponin in FACS buffer.  For antibody staining, cells were incubated for 15min at 4°C 
in the dark with the fluorochrome-labelled antibodies or isotype controls at the adequate 
concentration (see table below), followed by secondary antibody staining where required. 
Between staining steps, cells were washed with FACS buffer. For cell sorting, MACS buffer 
(PBS, 7.4% EDTA, 0.5% FCS) was used instead of FACS buffer.  
Apoptosis was measured using Annexin-V staining following manufacturer’s instructions 
(Invitrogen). Briefly, fresh 1X Annexin-binding buffer was prepared (1:10 diluted in dH2O) 
and kept on ice. Then, cells were washed in ice cold PBS. Next, washed cells were 
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centrifuged at 1200rpm 3min at 4°C, supernatant was discarded and samples were 
resuspended in 1X Annexin-binding buffer 100μl/probe. Appropriate amount of Annexin-V 
was added and samples were incubated 15min at 4°C. After the incubation, 400μl of 1X 
Annexin-binding buffer was added, gently mixed, kept on ice and immediately analysed via 
FACS.  
FlowJo software (Illumina) was used for all data analysis. 
Marker Fluorochrome Clone Dilution Isotypes Company 
LH analysis 
CD45 FITC 30-F11 1:50  biolegend 
CD31 488 MEC13.3 1:50 biolegend 
Epcam APC-Cy7 G8.8 1:100 biolegend 
CD49f PE GOH3 1:50 biolegend 
CD24 PE-Cy7 M1/69 1:200 biolegend 
BM-MSC and BM-MSC derived exosome characterization 
CD105 APC MJ7/18 1:50 Rat IgG2a,κ biolegend 
CD73 PB TY/11.8 1:50 Rat IgG1,κ biolegend 
CD90.2 (Ty-1.2) APC 53-2.1 1:100 Rat IgG2a,κ biolegend 
PDGRFα 
(CD140α) 
APC APA5 1:50 Rat IgG2a,κ biolegend 
Sca-1 (Ly-6A/E) PB D7 1:50 Rat IgG2a,κ biolegend 
CD44 PE/Cy5 IM7 1:10 Rat IgG2b,κ eBioscience 
CD29 PerCP-
eFluor®710 
HMβ1-1 1:100 Armenian 
Hamster IgG 
eBioscience 
CD117 (c-kit) PE/Cy7 104D2 1:50 Rat IgG2a,κ biolegend 
CD45 FITC 30-F11 1:50 Rat IgG2b,κ biolegend 
CD19 PE 6D5 1:100 Rat IgG2a,κ biolegend 
CD11b FITC M1/70 1:200 Rat IgG2b,κ biolegend 
CD31 PB 390 1:500 Rat IgG2a,κ biolegend 
CD34 FITC RAM34 1:50 Rat IgG2a,κ BD Pharmingen 
TER119 FITC TER-119 1:20 Rat IgG2b,κ Biolegend 
CD63 PE NVG-2 1:100 Rat IgG2a,κ biolegend 
Proliferation 
Mouse Anti Ki67 
Set 
FITC B56 20µl Mouse IgG1, κ BD Pharmingen 
Virus replication 
HA, goat   Polyclonal  1:75  abcam 
NP FITC 431 1:50 abcam 
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3.10 Statistics 
All data are given as mean ±SD. Statistical significance of two groups was analysed by 
unpaired Student’s t test. One-way ANOVA and post-hoc Tukey’s test were used when 
analysing statistical difference of three groups. All statistical analysis was performed with 
GraphPad Prism 5. Significance was assumed when p value was less than 0.05, and indicated 
as *p<0.05, **p<0.01 and ***p<0.005, accordingly. 
 
 
 
 
 
 
 
 
 
 
 
 
IgG, donkey anti-
goat 
Alex Fluor 647 Polyclonal 1:500 Invitrogen 
Cell sorting (MSC) 
CD45 FITC 30-F11 1:50  biolegend 
TER119 FITC TER-119 1:20 biolegend 
PDGRFα/CD140 APC APA5 1:50 biolegend 
Sca-1/Ly-6A/E PB D7 1:50 biolegend 
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4. Results 
4.1 BM-MSC isolation and characterization 
BM-MSCs were isolated by cell sorting from freshly prepared bone marrow cell suspension. 
First, hematopoietic cells defined as CD45 and TER119 positive cells were gated out and 
then the population of interest, the BM-MSC, was selected upon high expression of Sca-1 and 
PDGFRα (Figure 4-1). BM-MSC constitute a tiny population within the whole bone marrow 
cell pool (0.05 – 0.1%). Sorted CD45-Ter119-Sca1+PDGFRα+ cells displayed a purity >90%. 
 
 
 
 
 
 
 
 
 
Figure 4-1. Gating strategy for BM-MSC separation by FACS. The target population is phenotyped as CD45
-
Ter119
-
Sca1
+PDGFRα+.  
Sorted BM-MSCs were seeded on plastic plates and rapidly showed adherence as well as a 
fibroblast like shape (Figure 4-2A). BM-MSC were kept in culture (until passage 20) and 
their typical phenotype was preserved at least until passage 18. Figure 4-2B shows a 
representative image of their phenotype in culture at passage 8. 
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Figure 4-2. Microscopy images of BM-MSC at 3 and 5 days post-sort (A), and at passage 8 (B). 
Sorted BM-MSC were analysed at passage 5 by flow cytometry for surface marker 
expression. The analysis confirmed their MSC identity as they uniformly expressed the 
typical mesenchymal stem cell markers CD29 (Integrin β1), CD44 and CD105 (Endoglin), as 
well as CD90 (Thy-1) and Sca-1 (Ly-6A/E). These cells were negative for hematopoietic 
markers as CD45 (pan-leukocyte marker), CD19 (B-cell marker), CD11b (Integrin-α-M – 
monocyte, macrophage marker), CD117 (c-Kit – hematopoietic stem cell marker), and CD31 
(PECAM-1 – expressed on endothelial cells, monocytes, neutrophils, platelets) (Figure 4-3). 
They were positive for CD34, usually described as a hematopoietic progenitor and 
endothelial cell marker, and negative for CD73 (ecto 5’ nucleotidase), another mesenchymal 
stem cell marker). 
 
Figure 4-3. Representative histograms of flow cytometry analysis of BM-MSC of passage 5, confirming the 
BM-MSC phenotype according to consensus definitions. 
50µm 50µm
Day 3 Day 5 P8
50µm
P1
A B
44 
 
Moreover, the potential of differentiation of passage 5 BM-MSC was also tested. Under 
specific consensus conditions, BM-MSC were able to enter adipogenesis, osteogenesis and 
chondrogenesis differentiation processes and to give rise to adipocytes, osteocytes and 
chondrocytes as defined by light microscopy with positive staining for Oil-Red, Alizarin-red 
and Alcian-blue respectively (Figure 4-4).  
 
 
 
 
 
 
 
 
Figure 4-4. Microscopy images of differentiated BM-MSC. Top panel: unstained samples and bottom panel: 
stained samples with Oil-Red (adipocytes), Alizarin-red (osteocytes), Alcian-blue (chondrocytes). 
Taking together, isolated BM-MSCs fulfil the consensus criteria for the definition of 
multipotent mesenchymal stromal (stem) cells (typical MSC phenotype after many passages, 
positivity for MSC expression markers and negativity for markers of hematopoietic cell 
origin, as well as differentiation capacity to three lineages [149]).  
4.2 BM-MSC exert a protective role on infected AEC in vitro by 
stimulating alveolar proliferation and anti-viral programs 
To test the protective effect of BM-MSC, a co-culture model was established of primary 
alveolar epithelial cells (AEC) with primary BM-MSC to determine if BM-MSC can improve 
AEC survival to influenza challenge. AECs were infected with PR/8 and co-cultured with or 
without primary murine BM-MSC. A genome array was performed comparing the profiles of 
infected AEC alone (iAEC) and of infected AEC in presence of BM-MSC (iAEC-M) (Figure 
4-5A). Microarray analysis revealed upregulation of 457 genes (green) and downregulation of 
Adipogenesis Osteogenesis Chondrogenesis 
50 µ m 5 0 µ m 1 0 µ m 
1 0 µ m 50 µ m 1 0 µ m 
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234 genes (red) in iAEC-M in comparison to iAEC (p<0.05) as demonstrated by a volcano 
plot (Figure 4-5B). Presence of BM-MSC activates a proliferation and survival program in 
infected AEC as shown by significant increase of genes involved in cell division, mitosis and 
cell cycle GO pathways. Importantly, BM-MSC strongly induce genes associated with type I 
interferon signaling and antiviral response genes in infected epithelial cells (Figure 4-5C); for 
example, the virus resistance genes Mx2, Tetherin (Bst2) and viperin (Rsad2) are up-
regulated in iAECs-M compared to iAEC (not shown). 
 
Figure 4-5. (A) Hierarchical clustering and heat map analysis of individual gene expression profiles of iAEC-M 
versus iAEC at 24h post IV infection. Red bars indicate lower expression levels; green bars represent high 
expression levels. (B) Volcano plot comparing genes expression in iAEC-M versus iAEC 24h post IV infection. 
Probes identified as significant are labelled on the plot (p<0.05). (C) Top GO pathways identified in iAEC-M 
compared with iAEC using microarray analysis. 
These data suggest that BM-MSC reprogram infected AEC to activate proliferative/survival 
signatures, but also induce antiviral programs. To confirm this at a phenotypic level, analysis 
of AEC proliferation and extent of viral infection was performed by flow cytometry. During 
IV infection, BM-MSC presence drastically increases the proportion of proliferating AEC as 
defined by Ki67 positive cells (Figure 4-6A, B). Of note, BM-MSCs foster epithelial 
proliferation at all analysed time points to a level highly exceeding proliferation of non-
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infected AEC. Moreover, virus spread was significantly abolished in infected AECs in co-
culture with BM-MSC, as the number of infected cells defined as hemagglutinin (HA) 
positive was 4 times and 7 times lower at 24 and 48h pi, respectively, compared with infected 
AECs alone (Figure 4-6 C, D). As PR/8 infection of AEC had been started without BM-MSC 
in the iAEC-M group, the initial infection rate was similar in all conditions, and as expected, 
no difference in virus-positive cells was observed after 6h which corresponds to one PR/8 
replication cycle. 
Figure 4-6. (A) Quantification of Ki-67 positive AECs. (B) Representative histograms of Ki67 staining of AEC. 
(C) Quantification of virus presence in AECs as determined by hemagglutinin (HA) surface staining. (D) 
Representative histogram of HA staining of AECs. Grey pattern, non-infected AECs alone; black pattern, 
infected AECs alone; red pattern, infected AECs co-cultured with BM-MSCs. iAEC – infected AECs, iAEC-M 
– infected AECs in co-culture with BM-MSCs. Error bars represent SD (n=3). Significance was assumed when 
p value was less than 0.05, *p<0.05, **p<0.01 and ***p<0.005 accordingly.  
As high IV infection rates in the alveolar epithelium in vivo together with inflammatory 
injury results in severe apoptotic alveolar epithelial damage, AEC apoptosis levels were 
measured in co-culture system. A significant reduction of Annexin V positive AEC in the 
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presence of BM-MSC at 24 and 48h pi was observed, what is comparable to levels of non-
infected AEC (Figure 4-7A, B). 
 
 
 
 
 
 
Figure 4-7. (A) Annexin-V representative dot plots after 48h pi. (B) Quantification of Annexin-V positive AECs 
at 6, 24 and 48h pi. Grey pattern, non -infected AECs; black pattern, infected AECs alone; red pattern, infected 
AECs co-cultured with BM-MSCs. iAEC – infected AECs, iAEC-M – infected AECs in co-culture with BM-
MSCs. Error bars represent SD (n=3). Significance was assumed when p value was less than 0.05, *p<0.05, 
**p<0.01 and ***p<0.005 accordingly. 
Of note, to exclude that BM-MSC themselves represented a source of viral replication, it was 
analysed whether BM-MSC got infected by PR/8. BM-MSC did neither get infected when 
incubated directly with 0.1 MOI of PR/8 for 24h (Figure 4-8), nor in co-culture with infected 
AECs (not shown). 
 
Taken together, these results demonstrate a highly protective effect of BM-MSC in an in vitro 
co-culture model with IV-infected AECs, as they induce an antiviral program in AECs 
associated with reduced viral spread, and as they drive anti-apoptotic and pro-proliferative 
signaling in these cells. These experimental data suggest that application of BM-MSC in IV-
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Figure 4-8. Representative histogram 
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infected mice would be highly protective through limitation of viral spread and preserving the 
AEC barrier necessary for barrier function and gas exchange. 
4.3 The protective role of BM-MSC on infected AEC is 
mediated by paracrine factors  
Considering the evidence that MSC exert their beneficial properties in a paracrine manner by 
releasing factors such as cytokines, growth factors and antimicrobial peptides in lung injury 
models [193, 211, 226], I investigated the potential to reproduce their effects observed in the 
experiments presented above by use of BM-MSC conditioned medium (CM) instead of direct 
co-culture. BM-MSC derived CM was generated collecting CM one day after the BM-MSC 
had been co-incubated with PR/8-infected AEC. Similar to direct co-culture of BM-MSC 
with AEC, BM-MSC-derived CM enhanced AEC proliferation and reduced virus spread in 
PR/8-infected AEC at 24h pi; AEC apoptosis was also strongly reduced in presence of BM-
MSC CM (Figure 4-9A-C). 
  
 
 
 
 
 
 
Figure 4-9. Quantitative analysis of virus-infected AEC (A), proliferation (B) and apoptosis (C) in AEC 
analysed by flow cytometry. HA, hemagglutinin. Error bars represent SD (n=3). Significance was assumed 
when p value was less than 0.05, *p<0.05, **p<0.01 and ***p<0.005 accordingly. 
Since the paracrine action of BM-MSC had been previously related to content released by 
extracellular vesicles and especially exosomes [228, 256, 261], BM-MSC derived exosomes 
were analysed and quantified by specific magnetic beads staining after quantification of the 
optimal amount of Dynabeads to capture exosomes from a defined volume of BM-MSC 
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culture supernatant, followed by flow cytometric analysis to specify the source of exosomes 
by BM-MSC surface marker expression on exosomes [332]. First, exosomes were captured 
with the specific conserved “exosome” markers CD81 and CD9, which are tetraspanins. Flow 
cytometry analysis revealed that most exosomes are positive for another tetraspanin, namely 
CD63 (Figure 4-10).  
 
 
 
  
 
 
Figure 4-10. Representative dot-plots for dynabead-exosome complex detection by flow cytometry. From all 
dynabead-exosome complexes excluding electronic noise (red square), only singlet events are included (middle 
plot, oval pattern), from which CD63 PE positive events are counted as exosomes (left down, red square – the 
target population; representative controls – left up).  
In addition, exosomes expressed CD29, CD140α and CD34, and were highly positive for 
CD105 and CD44 reflecting their cellular BM-MSC origin. As expected, isolated exosomes 
were negative for CD45 and CD11b. Sca-1, CD73 and CD90 expression could not be 
detected (Figure 4-11).  
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Figure 4-11. Representative histograms of flow cytometry analysis for surface markers of BM-MSC derived 
exosomes. 
In conclusion, BM-MSCs are a substantial source of exosomes contained in the CM, and 
exosomal content might mediate the effects of BM-MSC as previously described [265, 275, 
276].  
To investigate the signaling pathways activated in MSC in the presence of AEC, we 
compared mRNA expression levels of putative MSC cytokines in co-culture with AECs 
(AEC-M) or with infected AECs (iAEC-M) (Figure 4-12). The epithelial growth factors 
FGF10 (fibroblast growth factor 10) and FGF7, and the anti-apoptotic factor Sta-1 
(stanniocalcin 1) were found out to be upregulated in MSC in co-culture with iAECs as early 
as 6h pi. Expression levels of the anti-viral cytokine IFNβ and the AEC growth factor/anti-
apoptotic mediator GM-CSF (granulocyte-macrophage colony-stimulating factor) [277] were 
upregulated in MSC in co-culture with iAECs at 48h pi. Interestingly, VEGF (vascular 
endothelial growth factor) was highly expressed at a baseline and expression of this gene was 
increasing in a time dependent manner during co-culture with iAEC (Figure 4-12). These 
results show that specific growth factors, anti-apoptotic and anti-viral genes are induced in 
BM-MSC by co-culture with infected versus non-infected AEC, suggesting that they may 
perceive defined signals released from the virally infected, apoptotic AEC by a yet unknown 
mechanism, and provide factors to counteract viral infection and AEC death, and induce AEC 
repair. 
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Figure 4-12. Potential candidates involved in BM-MSC therapeutic effect. Error bars represent SD (n=3). 
FGF10, fibroblast growth factor 10; FGF7, fibroblast growth factor 7; Sta-1, Stanniocalcin 1; IFNβ, Interferon 
beta; GM-CSF, Granulocyte macrophage colony stimulating factor; VEGF, Vascular endothelial growth factor; 
AEC-M/iAEC-M, uninfected/ infected alveolar epithelial cells in co-culture with BM-MSC; PI, post infection. 
4.4 Intra-tracheal BM-MSC application improves survival and 
decreases ALI severity in mice challenged with influenza 
MSC application after IV infection has been performed intravenously and described 
inefficient to reduced IV-induced ALI by Gotts et al and Darwish et al [233, 278]. As shown 
in this thesis previously, BM-MSC have a beneficial paracrine effect on infected AEC in 
vitro, thus has been tested their potential in vivo after direct intrapulmonary deposition by the 
intra-tracheal route of application in PR/8-infected mice. 
To establish BM-MSC treatment as a therapeutic and not as a prophylactic approach, BM-
MSC were applied during the course of infection, when viral replication reached its peak, as 
previously determined by our research group [42]. Mice were first infected intra-tracheally 
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with 500pfu (Plaque forming unites) of PR/8 and treated with either primary BM-MSCs or 
control solution (PBS) or control cells (3T3 cells) at day 3 pi (Figure 4-13).   
 
 
 
 
 
 
 
 
Figure 4-13. Schematic representation of the in vivo BM-MSC treatment and time points for analyses. All 
C57BL/6 mice were infected with 500pfu PR/8, treated at day 3 pi with PBS/3T3/BM-MSC and monitored for 7 
or 14 days. 
Strikingly, all BM-MSC treated mice survived PR/8 infection until 14d pi and presented a 
reduced weight loss compared to control mice. All PR/8-infected mice started losing weight 
by 4d pi, but differently from PBS and 3T3 treatment groups, BM-MSC mice lost less weight 
and regained it from day 8 to 9 pi (Figure 4-14B). Of note, most PBS and 3T3 treated mice 
had to be euthanatized before 8d pi as they displayed serious IV-induced symptoms, 
according to a daily applied morbidity scoring system established and approved for this 
infection model (Figure 4-14A).  
Figure 4-14. (A) Kaplan-Maier curves of PR/8 infected mice treated with BM-MSC or 3T3 cells or PBS 3d pi. 
(B) Mean weight loss curve of PR/8 infected mice treated with BM-MSC or 3T3 cells or PBS (black, black 
dotted represents the only one survivor from the PBS treatment group) 3d pi of n=6 mice each. Significance was 
assumed when p value was less than 0.05, *p<0.05, **p<0.01 and ***p<0.005 accordingly. 
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As most PR/8-infected mice survived until day 7 but already displayed substantial morbidity 
at this time, it was assumed that this time point is suitable to assess alveolar-capillary barrier 
dysfunction by alveolar FITC-albumin leakage measurement. 
BM-MSC treatment of PR8 infected mice significantly reduced alveolar-capillary protein 
leakage compared with the mice treated with 3T3 cells or PBS (Figure 4-15).  
 
 
 
 
 
 
Additionally to alveolar leakage measurement, lung histology revealed edema (*) and 
accumulation of inflammatory cells (**) in mice treated with PBS or 3T3 cells on day 7 and 
day 14 (one mouse survived in PBS group, meanwhile in the 3T3 group no mouse survived 
until day 14) as expected after PR/8 challenge, whereas very subtle histological abnormalities 
were observed at day 7 or 14 in the BM-MSC treatment group (Figure 4-16).  
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Figure 4-15. Alveolar leakage in PR/8-infected 
differently treated C57BL/6 mice at 7d pi. Data are given 
as the ratio between FITC fluorescence in BALF and 
serum (arbitrary units, AU). PBS, volume control; 3T3, 
control fibroblasts; MSC, mesenchymal stem cells. Data 
are presented as means ± SD from n=5 mice. Significance 
was assumed when p value was less than 0.05, *p<0.05 
and **p<0.01 accordingly. 
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Figure 4-16. (A-F) Representative lung histology of PR/8 infected mice treated with PBS (A, D); 3T3 cells (B); 
BM-MSC (C, E) at day 7 (A-C) or day 14 (D-E) pi. One mouse survived from PBS group, however, no 3T3 cell 
treated mouse survived until the day 14. Scale bar – 100μm. Mouse lungs were stained with haematoxylin and 
eosin. * - edema, ** - accumulation of inflammatory cells. 
Quantification of the leukocyte numbers and composition in the BALF by Pappenheim-
stained cytospin differential counts revealed that BM-MSC treatment strongly reduced the 
inflammatory response, particularly recruitment of neutrophils, and to lesser extent, of 
lymphocytes. Of note, BM-MSC also prevented alveolar haemorrhage as demonstrated by 
quantification of erythrocytes in the BALF (Figure 4-17).  
 
 
 
 
 
 
Figure 4-17.  (A) Total cell number and (B) % of total BALF cells in 3T3 cell, BM-MSC or PBS-treated PR/8 
infected mice at 5dpi as quantified by microscopy of cytospin preparations (n=3). “Other” refers to 3T3 cells or 
BM-MSC regained by BAL. 3T3, control fibroblasts; MSC, mesenchymal stem cells. 
4.5 BM-MSC application in vivo enhances proliferation of 
epithelial cells and protects the AEC pool against influenza 
induced apoptosis 
During IV infection of the distal respiratory tract, the alveolar epithelial cells are the first 
targets of the virus which leads to epithelial barrier disruption. Previous work done in our lab 
[105] demonstrated the importance of the Epithelial Stem Progenitor cell (EpiSPC) pool, 
phenotyped as highly positive for EpCam and CD49f and CD24 intermedium, in stem cell-
mediated lung repair after PR/8 infection. 
To address whether BM-MSC would enhance stem cell-mediated lung regeneration, similarly 
to our in vitro measurements, the impact of BM-MSC administration on the AEC pool as well 
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on the EpiSPC pool with respect to proliferation after lung injury was analysed by FACS. 
The gating strategy of AEC and EpiSPC is shown in Figure 4-18. 
 
Figure 4-18. Representative dot-plots for AEC and EpiSPC (Epithelial stem progenitor cells) identification by 
FACS. First, CD45 and CD31 cells are gated out and the Epcam high population is selected (left). The target 
population of AECs is highly positive for Epcam and expresses CD49f only at moderate level (middle). The 
EpiSPC population highly expresses Epcam as well as CD49f and moderate levels of CD24 (right). AEC, 
alveolar epithelial cells. 
Proliferation of the AEC pool, assessed by Ki67 staining, was increased by a factor of 2 in 
the BM-MSC group compared to control mice. A statistical enhancement of the EpiSPC pool 
proliferation was as well observed after BM-MSC administration (Figure 4-19).  
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Figure 4-19. Quantification of Ki-67 positive cells in AECs (A) and in EpiSPC (B) pools from lungs of PR/8 
infected mice treated as indicated at 3d pi. Lines represent means of n=8 mice. Significance was assumed when 
p value was less than 0.05, *p<0.05. 
Of note, similar to in vitro data, viral replication in AECs (defined by the percentage of viral 
hemagglutinin positive cells by FACS) was strongly reduced in BM-MSC treated mice 
compared to PBS and 3T3 cell controls (Figure 4-20). Of note, the quantification of infected 
AEC was done at 5d pi when PR/8 replication usually reaches its peak in vivo. 
 
Figure 4-20. Quantification of HA (hemagglutinin) 
positive in AECs from lungs of PR/8 infected mice 
(treated at d3 as indicated) at 5d pi. Lines represent 
means (n=5). Significance was assumed when p value 
was less than 0.05, *p<0.05, **p<0.01 accordingly. 
 
 
 
As BM-MSC application in vivo increased epithelial (stem) cell proliferation and reduced 
AEC infection rates, further AEC apoptosis levels were analysed by Annexin-V staining. A 
clear difference between the three groups was observed. Apoptosis in AECs (Figure 4-21) 
was reduced by factor 2 in presence of BM-MSC. 
 
Figure 4-21. Quantification of Annexin-V positive 
AECs from lungs of mice analysed by FACS at 7d pi. 
All mice were infected with 500pfu PR/8 and treated 
as indicated at 3d pi. Lines represent means (n=8). 
Significance was assumed when p value was less than 
0.05, *p<0.05, **p<0.01 accordingly. 
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Taken together, these findings show that intrapulmonary BM-MSC application at 3d post 
IAV infection strongly reduces inflammatory lung injury and loss of barrier function, protects 
the alveolar epithelium and induces epithelial repair processes, resulting in highly improved 
survival. BM-MSC application into virus-infected lungs may therefore constitute a 
therapeutic approach in humans with severe virus-induced lung injury. 
4.6 Type I Interferon pathway is engaged to mediate the BM-
MSC anti-viral potential in vivo 
BM-MSC effects have been shown in the literature to be anti-inflammatory, immuno-
modulating or tissue repair stimulating in various other lung injury models [214, 230, 232, 
279]. Yet, it is not known if BM-MSC can exert pathogen-related or -specific effects. With 
respect to the in vitro and in vivo results and especially the genome array analysis showing 
upregulation of genes involved in interferon signaling, the hypothesis was raised that BM-
MSC exert a specific antiviral effect through induction or enhancement of interferon 
signaling in AEC. To test this PR/8 infected mice lacking the type I IFN receptor (ifnar-/- 
mice) were treated with wildtype (wt) BM-MSC or PBS control (Figure 4-22). 
 
Figure 4-22. Schematic picture showing interventions and sacrifice time point. All ifnar-/- mice were infected 
with 500pfu PR/8, treated at day 3pi with PBS or wt BM-MSC and sacrificed 5d pi. 
BM-MSC application increased AEC proliferation (Figure 4-23B) but, interestingly, did not 
reduce epithelial viral infection rates as quantified by detection of either HA on the AEC 
surface or detection of NP in the AEC cytoplasm (Figure 4-23A), in mice deficient for the 
type 1 interferon receptor. In addition, treatment with BM-MSC did not reduce AEC 
apoptosis in ifnar-/- mice (Figure 4-23C).  
Infection 
Intra - tracheal  
injection of   
PBS/ MSCs 
D0 D3 D5 
Sacrifice 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-23. Quantification of HA and NP positive (A), and Ki67 (B) and Annexin V (C) positive AECs from 
lungs of mice analysed by FACS at 5d pi. Ifnar-/- mice were infected with 500pfu PR/8 and treated at 3d pi as 
indicated. Lines represent means of n=6 Ifnar-/- mice. Significance was assumed when p value was less than 
0.05, *p<0.05.  
Taken together, these results demonstrate that BM-MSC exert a type I IFN-independent pro-
proliferative effect on the epithelium, and a type I IFN-dependent antiviral effect on AEC. 
Loss of the anti-apoptotic effect on AEC by BM-MSC in ifnar-/- mice is very likely a 
consequence of reduction of viral spread within the alveolar epithelial compartment.  
4.7 BM-MSC anti-viral potential can be amplified through 
poly I:C stimulation in vitro  
The data presented reveal that BM-MSC act – either directly or indirectly – via type I IFN 
and suggest that BM-MSC are capable of sensing IAV infection within the alveolar 
compartment. This raises the question whether BM-MSC can be primed or pre-conditioned 
ex vivo to improve their antiviral potential. Therefore, BM-MSC were stimulated with several 
viral PAMPs (pathogen-associated molecular patterns)/TLR agonists or cytokines, and their 
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antiviral potential in co-culture with iAEC was evaluated. For BM-MSC conditioning poly 
I:C (TLR3 agonist), R848 (TLR7 agonist), 5’ppp-dsRNA (RIG-I agonist), as well as TNFα 
and IFNβ were applied [166, 167, 169, 170, 280, 281]. HA FACS analysis of iAECs in co-
culture with pre-conditioned or unconditioned BM-MSC revealed no changes of the amount 
of HA positive (infected) AEC after stimulation with R848, 5’ppp-dsRNA, TNFα or IFNβ. 
However, „sterile“ priming of BM-MSC with 1µg/ml of TLR3 agonist poly I:C further 
improved their anti-viral potential after 24h pi (Figure 4-24).  
 
 
Figure 4-24. Quantification of HA positive AECs by FACS at 24h pi. Bars represent means and SD (n=5). 
Significance was assumed when p value was less than 0.05, *p<0.05, **p<0.01 and ***p<0.001 accordingly.  
iAEC, infected AECs; iAEC-M, infected AECs in co-culture with BM-MSCs; iAEC-Ms, infected AECs in co-
culture with BM-MSC stimulated with 1μg/ml poly I:C. 
These results show that the anti-viral potential of BM-MSC can be enhanced by pre-
conditioning with TLR3 signaling activators, suggesting that BM-MSC pre-conditioning or 
priming can be taken into account to enhance particular beneficial properties (in this case, 
antiviral effects) prior to their application in vivo. 
 
 
    
 
0
5
10
15
20
iAEC iAEC-M iAEC-Ms
%
 H
A
+
 (
%
 o
f 
to
ta
l)
 ** 
*** 
* 
60 
 
5. Discussion 
Acute lung injury and ARDS due to pneumonia are severe conditions with no specific 
treatment available. Despite active research in understanding their pathology, ALI/ARDS 
remains a major cause of death in critical ill patients with a high mortality rate of roughly 
40% [89, 282].  
The main focus of this study was BM-MSC application as therapeutic approach, which has 
been attributed beneficial effects in different inflammation-injury conditions of the lung 
including those induced by LPS, bleomycin or live bacteria [158, 160, 164, 172, 192, 193, 
196-239].  
The efficacy of BM-MSC therapy will depend on the phenotype of MSC preparations. 
Isolation and purification of murine MSC is more challenging than from humans due to low 
amount in bone marrow and also frequent contamination with non-mesenchymal cells during 
the isolation process and cultures. In this study, to isolate primary MSC from murine bone 
marrow, a BM-MSC isolation protocol established by Houlihan et al. [131] was adapted.  As 
BM-MSC are found to be localised in the perivascular zone of bone marrow [134, 135], a 
collagenase A digestion was applied. Next, the cells were FACS sorted. Thus, a BM-MSC 
population with purity of >95% representing 0.05-0.1% cells from the whole bone marrow 
nuclear cell pool was achieved. The purified fibroblast-like cells expressed high levels of the 
typical consensus markers CD29, CD44 and CD105, as well as CD90 and Sca-1. Moreover, 
the results indicated that these cells are negative for CD45, CD19, CD11b, CD117 and CD31. 
Interestingly, using the before mentioned isolation protocol BM-MSC expressed CD34, a 
non-typical MSC marker, and did not express CD73 – a standard MSC marker. Expression of 
CD34 on MSC is still debated [283], as it is commonly used as a specific marker for muscle 
stem cells [284, 285] or vascular progenitor cells [286, 287]. However, several studies 
demonstrated that adipose tissue derived MSC [124, 288] or freshly isolated BM-MSC [289, 
290] express CD34. Little is known why and if the isolated MSC can lack CD73 expression 
[291]. After all, surface marker expression in murine MSC is not yet established completely 
[134, 289, 290, 292, 293]. In addition, the primary BM-MSC preserved a typical fibroblast 
like shape and the before mentioned marker characteristics, displayed high proliferation rates 
and differentiation potential into mesenchymal lineages (adipocytes, osteoblasts and 
chondrocytes) until passage 18 and therefore fulfilled the consensus paper of the International 
Society for Cellular Therapy (ISCT) MSC definition criteria [149]. Variation in marker 
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expression can be explained by isolation protocol specificities as well as by the multiple 
passages and cultivation conditions [131, 289, 290, 292-296]. 
The versatile features of BM-MSCs have been widely discussed and examined in different 
injury models. Many studies focused on their potential to stimulate regeneration of different 
tissues [190, 199, 204], their anti-bacterial, anti-inflammatory effects [169, 209, 210] as well 
as anti-apoptotic properties [185, 261]. In the in vitro experiments it was observed, that 
primary BM-MSC protected AEC from IAV induced injury via the following mechanisms. 
First, the increased proliferation of iAECs was noted. Moreover, the reduction of viral 
presence in AEC by BM-MSC suggests a specific viral sensing mechanism resulting in anti-
viral properties, and not only a non-specific tissue protection effect. As a consequence, the 
iAEC underwent less apoptosis. To a large extent, the therapeutic efficacy of MSC is 
associated to their capacity to secrete multiple soluble factors in response to environmental 
stimuli [182, 188, 189, 245, 269, 297, 298]. The paracrine action of BM-MSC was tested 
using BM-MSC CM. BM-MSC CM showed a beneficial effect towards IAV induced AEC 
damage via reduced viral replication, increased AEC proliferation and consequently, 
decreased apoptosis. However, the increase in proliferation rate was twice less with CM 
compared to when BM-MSC were present, suggesting that the factors involved in AEC 
proliferation might be short-acting and need constant release by BM-MSC, or repeated 
application of BM-MSC derived CM. Moreover, recent studies show that the MSC secretome 
as opposed to whole cell application may be not sufficient to repair the organ damage [227, 
279]. Certainly, MSC can exert their paracrine actions in different ways – by release of 
mediators or cytokines, via exosomes or microparticles [299], and even via mitochondrial 
transfer to AEC in vivo [172] suggesting that also direct cell-cell interactions may play a role 
and BM-MSC mechanisms of action is more complex. The presented qPCR data revealed 
that expression of different genes in BM-MSC (growth factors, as FGF7, FGF10, VEGF; 
anti-apoptotic molecules as Sta-1; anti-viral IFN-β) is initiated with different kinetics, 
suggesting that BM-MSC may be capable of sensing the particular “need” of the 
infected/injured epithelium and may respond accordingly in the different phases of damage. 
Further, the potential of BM-MSC application in vivo was investigated in a mouse model of 
severe IV induced pneumonia. Considering MSC homing to injured lungs, several studies 
demonstrated pulmonary engraftment after intravenous application [205, 300-303], and some 
of them showed that MSC can differentiate into alveolar epithelium or endothelial cells [147, 
303-306], suggesting that MSC could be used to regenerate lung tissue. Yet, these data 
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remain questioned by other investigations, showing that systemically installed MSC 
engraftment rates in lung are lower than 1% [230, 307, 308]. Moreover, as intravenous MSC 
application has been described as inefficient or low-efficient in the context of IV-induced 
ALI/ARDS [233, 278], the intrapulmonary application of BM-MSC was tested by the intra-
tracheal route. Local application at an early time point (3d pi) resulted in a significant 
histological improvement in the extent of lung injury. Additionally, significant reduction in 
inflammation with ameliorated neutrophil influx into alveoli, edema and haemorrhage was 
observed in mice treated with BM-MSC. Moreover, as demonstrated in this thesis, a 
significant survival advantage was observed when the BM-MSCs were applied 3d pi. BM-
MSC stimulated AEC proliferation and increased their survival and induced EpiSPC-
mediated repair responses, which is shown to be important in lung regeneration [78]. The 
mice treated with BM-MSC at 3d pi furthermore showed increased virus clearance, 
highlighting the multiple beneficial effects of these cells in vivo and demonstrating that local 
application directly to the site of infection as opposed to systemic application (where MSC 
accumulate in the lung vasculature but rarely reach the alveoli) may be required to engage 
their full anti-viral, anti-inflammatory and regenerative potential. These findings imply that 
BM-MSC need to sense pathogen PAMPs or injury-induced, cell-specific DAMPs (danger-
associated molecular patterns) at the site of infection/damage to deploy their full spectrum of 
beneficial action at the right time. This concept is further supported by the finding that pre-
conditioning of BM-MSC by a TLR3 ligand improves their anti-viral properties.  
In line, genome array analysis demonstrated that several virus resistance (Mx2, 
Bst2/Tetherin, Rsad2/Viperin, and Oas3) and numerous interferon signaling related genes 
(Ifna1, Ifi genes, GTPases, Trim56 etc.) were upregulated in iAEC in co-culture with BM-
MSC compared to mono-cultured iAEC. Moreover, expression of the IFNβ gene was 
increased in MSC in co-culture with iAECs. Given that virus clearance and apoptosis, 
contrary to AEC proliferation, were unchanged in AEC after BM-MSC application in PR/8 
infected ifnar-deficient mice, these data suggest that BM-MSC might sense viral presence, 
e.g. via PAMPS such as double-stranded RNA, and upregulate anti-viral factors such as type 
I IFNs which induce the mentioned anti-viral programs in AEC. Type I IFNs are critical 
effectors of the innate immune response to IAV infection and highly relevant to clear viral 
infections including IV [36, 42]. Of note, direct infection of BM-MSC (at least in the in vitro 
assays) was not observed, suggesting that anti-viral “priming” of these cells was not 
dependent on viral replication in BM-MSC. Noteworthy, the regenerative (e.g. pro-
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proliferative) effects of BM-MSC in vivo, likely mediated by release of growth factors [182-
186, 188-191] were still observed in ifnar-deficient mice and therefore occurred 
independently of type I IFN.   
There are several limitations in using BM-MSC for therapeutic applications. One major issue 
in stem cell research as well as cellular therapy is the immunogenicity of the cells meaning 
that transplantation can be “rejected” by the host [103]. Also, senescence due to 
chromosomal instability of isolated MSC or MSC isolated from elder murine donors [309, 
310] and potential of malignant transformation has to be considered. Additionally, gradual 
loss of their stemness during ex vivo expansion [311] must be taken into account. For in vitro 
as well as in vivo approaches described in this thesis were used 8-12 passage cryopreserved 
BM-MSC from healthy 10-12-week mice donors. Cryopreservation has been described to 
have no influence on MSC replication and growth as well [312]. However, few studies 
observed that this procedure can affect immunomodulatory properties of MSC in vitro [313, 
314]. For all studies, BM-MSC were cultivated 1-2 days before application. No visible tumor 
outgrowth in the lung sections have been noticed, however, the time course of 14 days is 
likely to be too short to rule out this phenomenon and a longitudinal study with repeated 
MSC application would be necessary to better determine the risk of tumor formation as 
described in few studies [315, 316].  
Another issue to consider is that MSC display very strong anti-inflammatory properties, and 
the susceptibility to bacterial superinfection after viral pneumonia, very commonly observed 
in humans [55, 317], after MSC application need to be tested [5, 55, 317] if repeated BM-
MSC applications are used as therapeutics. However, we did not observe any signs of 
bacterial superinfection in BM-MSC treated animals during 14d observation period, and 
previous reports demonstrated potent specific anti-bacterial effects of MSC apart from anti-
inflammatory properties [209]. An additional point to discuss is their dosage. There is no 
defined protocol for intra-tracheal application of BM-MSC and the dosage varies from 1-
10^5 to 5x10^6 in mice [209, 212, 239, 318]. For each experiment, I delivered 2.5x10^5 cells 
per 24-26g mouse and a dosage of more than 5x10^5 in 40μl volume was not well tolerated. 
It will have to be addressed whether the number of cells applied into the lung can be reduced 
to further increase safety of application, particularly when in vitro pre-conditioning 
approaches will be applied to enhance their efficacy prior to application.  
64 
 
Further questions to be answered relate to BM-MSC application in ALI induced by different 
IAV strains. To date, there is one study showing their beneficial effect ameliorating H5N1 
induced lung injury and modestly improving mouse survival [319]. However, this study 
focuses on intravenous application and addresses particularly MSC anti-inflammatory 
properties. Another question is how the anti-viral MSC effects could be amplified in vitro to 
increase beneficial therapeutic potential for applications in vivo. Several investigations 
focused on enhancing MSC anti-apoptotic, anti-inflammatory or immunomodulatory 
potential [167, 320, 321], yet studies focusing on “virus-specific” priming of MSC are 
lacking. In this thesis described in vitro BM-MSC stimulation experiment showed promising 
results and suggested targeting them via TLR3 activation could be one such strategy. 
Moreover, there is an ongoing debate if and how BM-MSC could be directly attracted from 
bone marrow to the site of injury, or how homing of intravenously applied MSC into injured 
organs could be improved by endowing them with certain chemokine receptors or adhesion 
molecules (for example, CXCR4 [322, 323] or CXCL9 [324], Vascular cell adhesion 
molecule (VCAM)-1/CD106, endoglin/CD105 or intercellular adhesion molecule ICAM-1/3 
(CD54 and CD50 respectively) [325]) to avoid the intrapulmonary application route, which is 
challenging in ARDS patients. Strategies of direct recruitment from the bone marrow to the 
injured organ excludes pre-conditioning, but could be beneficial, as changes in cultivation 
conditions can easily stimulate BM-MSC differentiation in vitro leading to phenotype 
changes and possibly reduced beneficial potential [326, 327].  
Concluding, as the interest regarding their therapeutic potential grows and more and more 
clinical trials use BM-MSC in phase I and II studies [328-330], the current thesis 
demonstrates that early local treatment with BM-MSC in IAV induced ALI provides a 
significant survival advantage due to multifactorial mechanisms. First, it decreased lung 
edema and inflammation. Second, it improves lung repair-promoting AEC and EpiSPC 
proliferation. And most important, it has anti-viral effects with consequently decreased AEC 
apoptosis/lung injury levels. Moreover, the upregulation of type I IFN-associated signaling 
pathways suggests that these cells engage innate anti-viral strategies to enhance their 
therapeutic potential. Given that, current BM-MSC applications in ALI/ARDS in humans 
show promising results. This study demonstrates for the first time that MSC act in an anti-
viral way, provides important knowledge on the molecular mechanisms underlying these 
effects, and demonstrates that local application might be more effective compared to systemic 
application.   
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6. Summary 
Influenza virus (IV) infects the upper respiratory tract and occasionally spreads to the 
alveolar compartment causing primary IV pneumonia. This frequently progresses to acute 
respiratory distress syndrome (ARDS) with severe alveolar damage, lung edema and 
hypoxemia, requiring mechanical ventilation or extracorporeal membrane oxygenation 
(ECMO) procedures. Antiviral therapies are only effective in the very beginning of infection 
and specific treatment strategies for IV-induced ARDS are still lacking. Mesenchymal stem 
cells (MSC) are multi-potent stromal cells with anti-inflammatory and regenerative potential: 
recently they were attributed a beneficial role in acute and chronic lung injury. This study 
investigated MSC delivery into the lung as a promising treatment strategy in IV-induced 
ARDS. 
In this study MSC were isolated from bone marrow (mBM-MSC) of C57Bl6. These MSC had 
fibroblast-like shape and expressed stem cell-specific markers and demonstrated de-
differentiation potential upon defined culture conditions. No phenotypic changes were 
observed until passage 18. Genome array analysis revealed a strong up-regulation of the 
genes involved in cell proliferation (cell division, cyclins), in interferon signaling (ISGs) and 
virus resistance (Mx2, Bst2/Tetherin) in infected alveolar epithelial cells (iAECs) co-cultured 
with BM-MSC compared to iAECs in monoculture. In ex vivo infection experiments, BM-
MSC as well as their conditioned medium (CM) strongly diminished IV replication, 
increased AEC regeneration and consequently decreased IV-induced AEC apoptosis.  
In vivo, intra-tracheal instillation of BM-MSC into C57BL/6 mice after 3 days post IV 
challenge strongly increased IV clearance, decreased alveolar injury and was associated with 
better outcome. Of note, BM-MSCs also increased the regenerative response of the epithelial 
stem/progenitor cell pool of the distal lung in vivo. Interferon alpha and beta receptor 
knockout (ifnar-/-) mice after IV infection could not clear the virus even under BM-MSCs 
treatment, demonstrating that the type I IFN pathway is responsible for the BM-MSC anti-
viral (and concomitantly, anti-apoptotic) potential in vivo.  
In conclusion, our ex vivo as well as in vivo experiments show a beneficial role of BM-MSCs 
in IV pneumonia and demonstrate the  therapeutic potential of these cells in IV-induced lung 
injury. Furthermore, the upregulation of type I IFN signaling-related pathways suggests that 
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these cells are activated in a pathogen-specific way in presence of virus, which enhances their 
beneficial properties.  
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7. Zusammenfassung 
Influenza Virus (IV) infiziert die oberen Atemwege, kann sich aber auch bis in die Alveolen 
ausbreiten und eine primäre virale Pneumonie verursachen. In schweren Fällen kommt es 
zum akuten Lungenversagen (Acute Lung Injury(ALI)/ Acute Respiratory Distress Syndrome 
(ARDS)). ARDS ist gekennzeichnet durch eine schwere Schädigung des alveolären Epithels, 
die Ausbildung einer refraktären Hypoxämie und die Bildung von Lungenödemen. Eine 
antivirale Therapie ist nur in den ersten Stunden nach der Infektion wirksam, weitere 
Therapiemöglichkeiten für IV-induziertes ALI/ARDS sind noch nicht vorhanden. 
Mesenchymale Stammzellen (MSC) sind multipotente Zellen, denen seit kurzem eine 
positive Wirkung auf die Entzündungsauflösung und Regenerierung des Lungenepithels bei 
akuter oder chronischer Verletzung zugeschrieben wird. In der vorliegenden Arbeit wurde die 
intratracheale Applikation von MSC als vielversprechende Behandlungsmöglichkeit bei IV-
induziertem ARDS untersucht.  
In Rahmen dieser Studie wurden MSC aus dem Knochenmark (murine bone marrow MSC 
(BM-MSC)) von C57BL/6 Mäusen gewonnen. BM-MSC haben eine fibroblastenartige Form, 
exprimieren stammzellspezifische Marker und besitzen das Potential unter bestimmten 
Kulturbedingungen in andere Zelltypen zu differenzieren. Bis Passage 18 konnten keine 
phänotypischen Veränderungen in isolierten BM-MSC beobachtet werden. Der Einfluss von 
BM-MSC auf IV-infizierte primäre alveoläre Epithelzellen (infected alveolar epithelial cells 
(iAEC)) wurde in einem in vitro Ko-Kulturmodell untersucht und mit iAEC in Monokultur 
verglichen. Die Expressionsanalyse von ko-kultivierten iAEC zeigte eine deutliche 
Hochregulation von Genen, beteiligt an Prozessen der Zellproliferation (Zellteilung, Cycline), 
Interferon-Signalwegen (ISGs), sowie von Virusresistenzgenen (Mx2, Bst2/Tetherin). Des 
Weiteren wiesen iAEC in Ko-Kultur oder durch Zugabe von MSC-konditioniertem Medium 
eine stark verminderte Apoptose- und IV Replikationsrate, sowie eine erhöhte 
Regenerationsfähigkeit auf.  
In in vivo Versuchen konnte durch die intratracheale Applikation von BM-MSC die Viruslast 
sowie die Schädigung des Alveolarepithels in IV-infizierten Mäusen deutlich verringert 
werden. Darüber hinaus konnte auch eine erhöhte Proliferationsrate der epithelialen 
Stamm/Progenitorzellen in der distalen Lunge detektiert werden. Insgesamt zeigt dies eine 
Verbesserung der Regenerationsfähigkeit des Lungenepithels durch die Gabe von BM-MSC. 
In weiteren in vivo Infektionsversuchen mit Interferon-/-Rezeptor-Knockout-Mäusen 
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(ifnar-/-) konnte gezeigt werden, dass Typ I Interferon-induzierte Signalwege an den 
beobachteten antiviralen Effekten der BM-MSC-Gabe beteiligt sind. Infizierte ifnar-/- -
Mäuse waren, auch nach BM-MSC-Applikation, nicht in der Lage die Viruslast in der Lunge 
zu verringern.  
Zusammenfassend ist zu sagen, dass die positive Rolle von BM-MSC in der IV-induzierten 
Pneumonie und dem damit verbunden therapeutischen Potential in in vitro und in vivo 
Versuchen klar dargelegt werden konnte. Des Weiteren lässt die Hochregulation der durch 
Typ I Interferon induzierten Signalwege vermuten, dass BM-MSC in der Gegenwart von IV 
spezifisch aktiviert werden, wodurch sich ihre vorteilhaften anti-viralen Eigenschaften noch 
erhöhen.  
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9. Supplement  
9.1 List of Figures 
Figure 1-1 Schematic picture of influenza virus structure, adapted from http://visual-
science.com  
Figure 1-2 IAV replication cycle in alveolar epithelial cell (AEC) [24] 
Figure 1-3 Host immune response to IAV infection [24] 
Figure 1-4 Chest X-ray images illustrating early ALI (A) and ARDS (B). Adapted 
from [58] 
Figure 1-5 The schematic picture representative normal and injured alveolus during 
the ALI/ARDS [57] 
Figure 1-6 Schematic picture representing location of MSCs in the bone marrow 
subendothelial region, adapted from Bianco et al [136] 
Figure 1-7 Differentiation and self-renewal potential of BM-MSC [137] 
Figure 1-8 Polarization of MSC into pro- and anti-inflammatory phenotype [163]  
Figure 1-9 Paracrine effects of cultured MSCs [181] 
Figure 1-10 The potential beneficial paracrine action of intravenously or intra-
tracheally installed MSC. Adapted from [245] 
Figure 1-11 Schematic picture of exosome and its markers [260] 
 
Figure 3-1 Exosome isolation protocol 
Figure 3-2 AEC co-culture with BM-MSC, 3T3 
Figure 3-3 AEC co-culture with BM-MSC derived Conditioned Medium 
 
Figure 4-1 Gating strategy for BM-MSC isolation by FACS. 
Figure 4 -2 Microscopy pictures of BM-MSC at day 3 and 5 post sort (A), and 
passage 8 (B) 
Figure 4-3 Representative histograms of flow cytometry analysis of BM-MSC 
marker expression 
Figure 4-4 Microscopy pictures of differentiated BM-MSC 
Figure 4-5 Hierarchical clustering and heat map analysis of individual gene 
expression profiles of iAEC-M versus iAEC at 24h post IV infection 
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Figure 4-6 Representative histograms and quantification graphs of Ki-67 and HA 
positive AECs, infected AECs or infected AECs in co-culture with BM-
MSC 
Figure 4-7 Representatives dot plots and quantification graphs of Annexin V positive 
AECs 
Figure 4-8 Representative histograms comparing infected versus non-infected MSC 
and isotype control 
Figure 4-9 Quantitative analysis of virus replication, proliferation and apoptosis in 
infected AEC versus infected AEC in presence of BM-MSC CM 
Figure 4-10 Representative dot-plots for dynabead-exosome complex detection by 
flow cytometry 
Figure 4-11 Representative histograms of flow cytometry analysis for surface markers 
of BM-MSC derived exosomes 
Figure 4-12 Potential candidates involved in BM-MSC therapeutic effect 
Figure 4-13 Schematic representation of interventions and sacrifice time points 
monitored for 7 or 14 days 
Figure 4-14 Kaplan-Meier curves of PR/8 infected mice treated with BM-MSC or 
3T3or PBS 3d pi 
Figure 4-15 Alveolar leakage in IV infected differently treated C57BL/6 mice at 7d pi 
Figure 4-16 Representative lung histological pictures of PR/8 infected mice treated 
with PBS, 3T3 and MSC at day 7 or day 14 pi 
Figure 4-17 Representative BALF cell quantification graphs of three different 
treatment groups at 5d pi 
Figure 4-18 Representative dot-plots for AEC and EpiSPC identification by FACS 
Figure 4-19 Quantification of Ki-67 positive AECs and EpiSPC of PR/8 infected 
differently treated mice 
Figure 4-20 Quantification of HA positive in AECs pool from LH of PR/8 infected 
mice treated at d3 at 5d pi 
Figure 4-21 Quantification of Annexin V positive AECs from LH analysed by FACS 
at 7d pi 
Figure 4-22 Schematic picture showing interventions and sacrifice time points of 
ifnar-/- mice 
Figure 4-23 Quantification of HA and NP positive, and Ki67 and Annexin V positive 
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AECs from LH (ifnar-/-) analysed by FACS at 5dpi 
Figure 4-24 Quantification of HA positive iAECs alone or in co-culture with BM-
MSC or poly I:C stimulated BM-MSC 
 
9.2 Materials: chemicals, antibodies, kits 
2-Propanol Sigma-Aldrich, Taufkirchen (DE) 
Accutase StemPro, Gibco, BRL, Karlsruhe (DE) 
Acetic acid Merc Millipore, Darmstadt (DE) 
Alcian Blue Sigma-Aldrich, Taufkirchen (DE) 
Alizarin Red Sigma-Aldrich, Taufkirchen (DE) 
Annexin binding buffer Life Technologies, Carlsbad (USA) 
Annexin V-Alex Fluor 647 Life Technologies, Carlsbad (USA) 
Atropine B.Braun, Melsungen (DE) 
Biotin-binder magnetic beads Life Technologies, Carlsbad (USA) 
BSA (Bovine serum albumin) Sigma-Aldrich, Taufkirchen (DE) 
Cell culture flask 75cm2, 175 cm2 Greiner, Nürtingen (DE) 
Cell culture plates, single- and multi-
well  
Greiner, Nürtingen (DE) 
Cell nylon net filters 20μm Merc Millipore, Darmstadt (DE) 
Cell strainer filters 40, 70 and 100μm BD Biosciences, San Jose (USA) 
Collagenase A Roche Diagnostics GmbH, Mannheim (DE) 
CryoPure tubes 1.5ml Sarstedt. Nümbrecht (DE) 
DAPI Sigma-Aldrich, Taufkirchen (DE) 
dH2O Pharmacia & Upjohn, Peapack (USA) 
Dispase Corning Life Sciences, Tewksbury (USA) 
DMEM (Dulbecco's Modified Eagle 
Medium) (1x) low glucose GlutaMax, 
supplement pyruvate 
Gibco, BRL, Karlsruhe (DE) 
DMEM (Dulbecco's Modified Eagle 
Medium) high glucose 
Gibco, BRL, Karlsruhe (DE) 
DMSO (Dimethyl sulfoxide) Sigma-Aldrich, Taufkirchen (DE) 
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Dnase Serva, Heidelberg (DE) 
dNTPáse (desoxynucleoside 
triphosphate) 
Thermo Scientific, Watham (USA) 
DPBS (Dulbecco's phosphate-buffer 
saline) 
Life Technologies, Carlsbad (USA) 
Dynabeads® Biotin Binder Invitrogen (NO) 
EDTA (Ethylenediaminetetraacetic 
acid) 
Roth, Karlsruhe (DE) 
Eosin G Solution Merc Millipore, Darmstadt (DE) 
Ethanol Sigma-Aldrich, Taufkirchen (DE) 
Exi-FBS™ Exosome-depleted FBS 
Medium 
System Biosciences, Palo Alto (USA) 
FCS (fetal calf serum) Life Technologies, Carlsbad (USA) 
FITC-Albumin Sigma-Aldrich, Taufkirchen (DE) 
Fluoromount™ Sigma-Aldrich, Taufkirchen (DE) 
GentleMACS C tubes Miltenyi Biotec, Bergisch Gladbach (DE) 
GW4869 (hydrochloride hydrate) R&D Systems, Minneapolis (USA) 
Haematoxylin solution Merc Millipore, Darmstadt (DE) 
HBSS (Hank's balanced salt solution) 
(1x), no phenol red 
Gibco, BRL, Karlsruhe (DE) 
HEPES Merc Millipore, Darmstadt (DE) 
hMSC Adipogenic Induction 
SingleQuots® 
Lonza, Walkerswill (USA) 
hMSC Adipogenic Maintenance 
SingleQuots® 
Lonza, Walkerswill (USA) 
hMSC Chondrogenic SingleQuots® Lonza, Walkerswill (USA) 
hMSC Osteogenic SingleQuots® Lonza, Walkerswill (USA) 
Hydrochloridic acid Sigma-Aldrich, Taufkirchen (DE) 
Isoflurane Abbott, Chicago (USA) 
Ketaminhydrochloride (Ketavet) Pharmacia & Upjohn, Peapack (USA) 
L-Glutamine [200mM] Gibco, BRL, Karlsruhe (DE) 
Lipofectamine 2000 Life Technologies, Carlsbad (USA) 
Methanol Roth, Karlsruhe (DE) 
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Mouse Mesenchymal Stem Cell 
Growth Medium 
Cyagen/OriCell™, Santa Clara (USA) 
mouse recombinant interferon-β pbl interferon source, Logan (USA) 
mTNFα (Tumor necrosis factor alpha, 
mouse) 
R&D Systems, Minneapolis (USA) 
NaCl 0.9% Pharmacia & Upjohn, Peapack (USA) 
NCR Protein-Free Cryopreservation 
Medium 
Cyagen/OriCell™, Santa Clara (USA) 
Oil-Red Merc Millipore, Darmstadt (DE) 
Parafilm American National, Greenwich (USA) 
Paraformaldehyde (PFA) Merc Millipore, Darmstadt (DE) 
Paraffin Leica biosystems, Nussloch (DE) 
PBS (Dulbecco's phosphate-buffer 
saline) containing MgCl 
PAN-Biotech, Aidenbach (DE) 
Penicillin/Streptomycin [5000U/l] Gibco, BRL, Karlsruhe (DE) 
Platinum SYBR Green qPCR 
SuperMix 
Life Technologies, Carlsbad (USA) 
Poly I:C Tocris, Bristol (UK) 
Polystyrene round-bottom tubes 5ml BD Biosciences, San Jose (USA) 
Polystyrene tubes 15ml and 50ml Greiner, Nürtingen (DE) 
Propodium iodide Sigma-Aldrich, Taufkirchen (DE) 
R848 (Imidazoquinoline compound) InvivoGen, San Diego (USA) 
Reaction tubes 0.5 and 1.5ml Eppendorf, Hamburg (DE) 
rmBMP-6 (Bone morphogenetic 
protein 6, recombinant mouse) 
R&D Systems, Minneapolis (USA) 
Rneasy Micro Kit Quiagen, Hilden (DE) 
Sandoglobulin Novartis, Basel (CH) 
Saponine Merc Millipore, Darmstadt (DE) 
Sodium Azid Merc Millipore, Darmstadt (DE) 
Syringe 1, 10 and 20ml B.Braun, Melsungen (DE) 
TGF-B3 (transforming growth factor 
3, mouse) 
Lonza, Walkerswill (USA) 
Transwell® permeable support 24 and Cornig, Kennebunk (USA) 
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12mm with 0.4μm Polyester 
Membrane 
Trypan Blue Stain 0.4% Gibco, BRL, Karlsruhe (DE) 
Trypsin-EDTA Merc Millipore, Darmstadt (DE) 
Trypsin-TPCK Worthington Biochemical, Lakewood (USA) 
Vectashield Mounting Medium 
(DAPI) 
Vector Laboratories, Burlingame (USA) 
Xylazine hydrochloride, Rompum Bayer AG, Leverkusen (DE) 
Xylole Merc Millipore, Darmstadt (DE) 
Antibodies 
Armenian Hamster IgG-
PerCP/eFluor710 
Ebioscience, Frankfurt (DE) 
biotinylated rat anti-mouse CD16/32 BD Biosciences, San Jose (USA) 
biotinylated rat anti-mouse CD31 BD Biosciences, San Jose (USA) 
biotinylated rat anti-mouse CD45 BD Biosciences, San Jose (USA) 
biotinylated rat anti-mouse CD81 biolegend, San Diego (USA) 
biotinylated rat anti-mouse CD9 biolegend, San Diego (USA) 
CD105-APC, MJ7/18, anti-mouse biolegend, San Diego (USA) 
CD117 (c-kit)-PE7Cy7, 104D2 biolegend, San Diego (USA) 
CD11b-PB, MI/70, anti-mouse biolegend, San Diego (USA) 
CD11c-FITC, N418, anti-mouse biolegend, San Diego (USA) 
CD19-PE, 6D5 biolegend, San Diego (USA) 
CD206-APC, C068C2, anti-mouse biolegend, San Diego (USA) 
CD24-PE-Cy7, M1/69, anti-mouse biolegend, San Diego (USA) 
CD29-PerCP/eFluor710, HMb1-1 Ebioscience, Frankfurt (DE) 
CD31-Alexa Fluor 488, MEC13.3, 
anti-mouse 
biolegend, San Diego (USA) 
CD31-PB, 390, anti-mouse biolegend, San Diego (USA) 
CD326 (Epcam)-APC/Cy7, G8.8, 
anti-mouse 
biolegend, San Diego (USA) 
CD326 (Epcam)-efluor450, G8.8, 
anti-mouse 
Ebioscience, Frankfurt (DE) 
CD34-FITC, RAM34 BD Biosciences, San Jose (USA) 
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CD40-PE/Cy5, 3/23, anti-mouse biolegend, San Diego (USA) 
CD44-PE/Cy5, D7 Ebioscience, Frankfurt (DE) 
CD45-APC, 30-F11, anti-mouse biolegend, San Diego (USA) 
CD45-FITC, 30-F11, anti-mouse biolegend, San Diego (USA) 
CD45-V450, 30-F11, anti-mouse BD Biosciences, San Jose (USA) 
CD49f-PE, GOH3, anti-mouse biolegend, San Diego (USA) 
CD63-PE, NVG-2 biolegend, San Diego (USA) 
CD73-PB, TY/11.8 biolegend, San Diego (USA) 
CD90.2-APC, 53-2.1 biolegend, San Diego (USA) 
Gr1 (Ly-6C)-PE/Cy7, RB6-8C5, anti-
mouse 
biolegend, San Diego (USA) 
HA-APC, goat polyclonal Abcam, Cambridge (UK) 
NP-FITC, 431, anti-mouse Abcam, Cambridge (UK) 
PDGFRα (CD140)-APC, APA5 biolegend, San Diego (USA) 
Rat IgG1, κ-PB biolegend, San Diego (USA) 
Rat IgG2a, κ-APC biolegend, San Diego (USA) 
Rat IgG2a, κ-FITC biolegend, San Diego (USA) 
Rat IgG2a, κ-PB biolegend, San Diego (USA) 
Rat IgG2a, κ-PE  biolegend, San Diego (USA) 
Rat IgG2a, κ-PE/Cy5 biolegend, San Diego (USA) 
Rat IgG2a, κ-PE/Cy7 biolegend, San Diego (USA) 
Rat IgG2b, k-FITC biolegend, San Diego (USA) 
Rat IgG2b, κ-PE/Cy5 biolegend, San Diego (USA) 
Sca-1/Ly-6A/E-PB, D7 biolegend, San Diego (USA) 
secondary goat Alexa Fluor 488 Life Technologies, Carlsbad (USA) 
secondary goat APC Life Technologies, Carlsbad (USA) 
secondary rabbit Alexa Fluor 488 Life Technologies, Carlsbad (USA) 
SiglecF-PE, E50-2440 BD Biosciences, San Jose (USA) 
Syrian Hamster IgG-APC biolegend, San Diego (USA) 
T1α-APC, 8.1.1., anti-mouse biolegend, San Diego (USA) 
TER119-FITC, TER-119 biolegend, San Diego (USA) 
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pro-SPC, anti-mouse Merc Millipore, Darmstadt (DE) 
Ki67-FITC, mouse anti-human BD Biosciences, San Jose (USA) 
BD Compensation Beads Plus BD Biosciences, San Jose (USA) 
ELISA  
Mouse IFNα, detection limit 12.5 
pg/ml 
Pbl interferon source, Logan (USA) 
Mouse IFNβ, detection limit 15.6 
pg/ml 
Pbl interferon source, Logan (USA) 
Mouse HGF, detection limit 400pg/ml Thermo Scientific, Watham (USA) 
Human KGF/FGF7 DuoSet, detection 
limit 31.2 pg/ml 
R&D Systems, Minneapolis (USA) 
9.3 Abbreviations 
°C Celsius 
3T3 Mouse embryonic fibroblast cell line 
AEC Alveolar epithelial cells 
AFC Alveolar fluid clearance 
ALI Acute lung injury 
AM Alveolar macrophage 
Ang-1 Angiopoietin 1 
APC Allophycocyanin 
ARDS Acute respiratory distress syndrome 
AU Arbitrary units  
BALF Bronchoalveolar lavage fluid 
bFGF Basic fibroblast growth factor 
BM Bone marrow 
BM-MSC Bone marrow derived mesenchymal stem cells 
BSA Bovine serum albumin 
Bst2 Bone marrow stromal antigen 2 
CARDS Caspase activation and recruitment domains 
CCL Chemokine ligands 
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CD Cluster of differentiation 
cDNA Complementary DNA. 
CM Conditioned medium 
CMV Cytomegalovirus 
CMV Cytomegalovirus 
CO2 Carbone dioxide 
CXCL C-X-C motif chemokine 
CXCR Chemokine receptor 
DAMPs Danger-associated molecular patterns 
DAPI 4',6-diamidino-2-phenylindole 
DC Dendritic cell 
dH2O Deionized water 
DMEM Dulbecco's modified Eagle's medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic Acid 
dNTP Deoxynucleosid triphosphate 
DPBS Dulbecco's phosphate buffer saline 
Dpi Days post infection 
dsDNA Double stranded DNA 
dsRNA Double stranded RNA 
ECMO Extracorporeal membrane oxygenation 
EDTA Ethylendinitrilotetraacetic acid 
EGF Epidermal growth factor 
eIF2α Eukaryotic translation initiation factor 2α 
ELISA Enzyme Linked Immunosorbent Assay 
EpCAM Epithelial cell adhesion molecule 
EPCs Endothelial progenitors 
EpiSPC Epithelial stem progenitor cell 
ESC Embryonic pluripotent stem cell 
EtOH Ethanol 
EV Extracellular vesicles 
FACS Fluorescence activated cell sorting, flow cytometry 
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FCS Fetal calf serum 
FGF Fibroblast growth factor 
FiO2 Fraction of inspired oxygen 
FITC Fluorescein isothiocyanate 
FSC Forward scatter 
G Gram 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GO Gene Ontology 
h Hours 
HA Hemagglutinin 
HBSS Hank's balanced salt solution 
HCl Hydrochloric acid 
HGF Hepatocyte growth factor 
HLA-G5 Human leukocyte antigen G5 
HSC Hematopoietic stem cells 
iAEC Infected alveolar epithelial cells 
iAEC-M Infected alveolar epithelial cells in co-culture with mesenchymal stem cells 
IAV Influenza A virus 
ICAM Intercellular adhesion molecule 
ICU Intensive Care Unit 
IDO Indoleamine 2,3-dioxygenase 
IFI Interferon-inducible genes 
IFN Type I Interferon 
IFNAR Interferon alpha/beta receptor 
IFNα Interferon alpha 
IFNβ Interferon beta 
IFNγ Interferon gamma 
Ig Immunoglobulin 
IGF-1 Insulin-like growth factor 1 
IL Interleukin 
IL-1R Interleukin 1 receptor 
IL1RN Interleukin 1 receptor antagonist 
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iNOS Inducible nitric oxide synthase 
iPSCs Induced pluripotent stem cells 
IRAK 1 Interleukin 1 receptor associated kinase 
ISGs IFN-stimulated genes 
It Intra-tracheal 
IV Influenza virus   
JAK/STAT Janus kinase/Signal Transducer and Activator of Transcription 
KC Keratinocyte-derived protein chemokine 
KEGG Kyoto Encyclopaedia of Genes and Genomes 
Kg Kilogram 
KGF Keratinocyte growth factor 
KO Knockout 
l  Litre 
LH Lung homogenate 
LIF Leukemia inhibitory factor 
LPI Lung permeability index  
LRT Lower respiratory tract 
M Molar 
m  Milli 
M1 Matrix protein 1 
M2 Matrix protein 2 
mAEC Murine alveolar epithelial cells 
MAPKs Mitogen-activated kinases 
MAVS Mitochondrial antiviral signalling protein 
mBM-MSC  Murine bone marrow-derived mesenchymal stem cells 
MCP-1 Monocyte Chemoattractant Protein-1 
M-CSF Macrophage colony-stimulating factor 
MDCK Madin Darbey Canine Kidney epithelial cell line  
MHC Histocompatibility complex 
Min Minute 
MIP-2 Macrophage inflammatory protein 2 
miRNA Micro ribonucleic acid 
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MMP Matrix metalloproteinases 
MOI Multiplicity of infection 
Mol Mole 
mRNA Messenger RNA 
MSC Mesenchymal stem cells 
mtDNA Mitochondrial DNA 
MVB Multi-vesicular bodies 
Mx2 MX dynamin like GTPase 2 
MyD88 Myeloid differentiation primary response gene 88 
n Nano 
NA Neuraminidase 
NaAz Sodium Azide 
NaCl Sodium chloride 
NEP Nuclear export protein 
NF-κB Kappa-light-chain-enhancer of activated B cells 
NLRP3 NOD-like receptor family member pyrin domain-containing 3 
NO Nitric oxide 
NOD Nucleotide oligomerization domain 
NOS Nitric oxide synthase 
NP Nucleoprotein 
OAS  2’5’-oligoadenylate synthetase  
PaO2 Partial pressure arterial oxygen 
PAMPs Pathogen-associated molecular patterns 
PB Pacific blue 
PB1 Polymerase protein basic 1 
PB2 Polymerase protein basic 2 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
PDGFRα Platelet derived growth factor receptor alpha 
PE Phycoerythrin 
PFA Paraformaldehyde 
Pfu Plaque forming units 
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PGE2 Prostaglandin E2 
pH Potentia hydrogenii 
pi Post infection 
PI Propidium iodide 
PIGF Placental growth factor 
PKR Protein kinase R 
PR/8 Influenza virus A/Puerto Rico/8/34 (H1N1) 
proSP-C Pro-surfactant protein C 
PRRs Pattern recognition receptors 
qRT-PCR Quantitative real-time polymerase chain reaction 
RANTES Regulated on activation, normal T cell expressed and secreted 
RIG-I Retinoic acid-inducible gene 1 
rmBMP-6 Bone morphogenetic protein 6, recombinant mouse 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
Rpm Rounds per minute 
Rsad2 Radical S-adenosyl methionine domain containing 2 
RT Room temperature 
s Second 
SA Sialic acid 
Sca-1 Stem cells antigen 1 
SCF Stem cell factor 
SD Standard deviation 
SDF-1 Stromal-derived factor1 
SEM Standard error of mean 
SOCS Suppressor of cytokine signalling 
SPF Specific pathogen free 
SPM Specialized pro-resolving mediators 
SSC Side scatter 
ssDNA Single stranded DNA 
ssRNA Single stranded RNA 
Sta-1 Stanniocalcin-1 
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TER119 Glycophorin-A associated antigen 
TGF-β Tumor growth factor beta 
TGF-3 Transforming growth factor 3 
TLR Toll-like receptor 
TNF Tumor necrosis factors 
TRAIL TNF-related apoptosis-induced ligand 
TRAF6 Tumor necrosis factors receptor associated factor 6 
TRIF TIR-domain-containing adapter-inducing interferon-beta  
TRIM25 Tripartite motif-containing protein 25 
TRIM56 Tripartite motif-containing protein 56 
Tsg101 Tumor susceptibility gene 101 
TSG-6 Tumor necrosis stimulated gene 6 
U Units 
URT Upper respiratory tract 
US United States 
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor 
vol Volume 
vRNP Viral ribonucleoprotein 
WHO World health organization 
wt Wildtype 
wt Weight 
μ Micro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Der Lebenslauf wurde aus der elektronischen 
Version der Arbeit entfernt. 
 
 
 
 
The curriculum vitae was removed from the 
electronic version of the paper. 
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